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Abstract
Argonaute (Ago) proteins interact with small non-coding RNAs, which guide them to comple-
mentary target RNAs to mediate gene silencing. e domain organization of Ago proteins clearly
reects their function. e ends of the small RNA are bound by the Mid and PAZ domains and the
structure of the PIWI domain closely resembles that of the endonuclease RNase H. Indeed, some
Ago proteins can cleave perfectly complementary target RNAs. Here, the endonucleolytically
inactive human Ago proteins Ago1, Ago3, and Ago4 were mutated to yield minimally changed,
catalytically active proteins. e generation of these mutants revealed several features that are
important for Ago cleavage activity, in particular two regions in the N-terminal domain and two
structural elements in the catalytic domain. e identication of these structural requirements
contributes essentially to our understanding of Ago-mediated silencing activity.
Ago proteins not only cleave their targets. In case of partial complementarity between small
RNA and target RNA, they recruit additional factors to mediate gene silencing. Here, predomi-
nant mechanisms are translational repression and reduction of target stability. Considering the
wide spectrum of gene regulation emanating from Ago proteins, it is important to understand
how the proteins are regulated themselves. Here, post-translational modications, in particular
phosphorylations, of Ago proteins were analyzed by mass spectrometry. Multiple endogenous
phosphorylation sites of Ago2 and its paralogues were detected. Among them are sites, which
are organized in phosphorylation clusters. e data generated in this thesis represents a valuable
resource for future analyses of Ago proteins and their modifying enzymes, which will provide
insights into the interplay of small RNA-guided gene silencing and signaling pathways.
e phosphorylation sites analyzed here were identied on endogenous Ago proteins. To pro-
vide large amounts of endogenous protein, a novel, peptide-based purication strategy was es-
tablished. Ago Anity Purication by Peptides (Ago-APP) is based on the interaction of Ago
proteins with a conserved binding partner, a member of the GW182 protein family. erefore, the
approach puries all four human Ago proteins and can even be applied species-independently.
Ago-APP represents a powerful tool for the characterization of diverse Ago complexes at the
levels of protein, small RNA, and target RNA.
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Zusammenfassung
Argonaute-(Ago-)Proteine interagieren mit kleinen, nicht-codierenden RNAs, welche sie zu kom-
plementa¨ren Ziel-RNAs leiten, um Genrepression zu vermieln. Die Doma¨nenorganisation von
Ago-Proteinen spiegelt deren Funktion deutlich wider. Die Enden der kleinen RNA werden durch
die Mid- und PAZ-Doma¨nen gebunden und die Struktur der PIWI-Doma¨ne a¨hnelt stark der der
Endonuklease RNase H. Tatsa¨chlich ko¨nnen einige Ago-Proteine perfekt komplementa¨re Ziel-
RNAs schneiden. Hier wurden Mutationen in die endonukleolytisch inaktiven humanen Ago-
Proteine Ago1, Ago3 und Ago4 eingefu¨hrt, um minimal vera¨nderte, katalytisch aktive Proteine
zu erhalten. Mit Hilfe dieser Mutanten wurden mehrere strukturelle Merkmale identiziert, die
wichtig fu¨r die Spalt-Aktivita¨t der Proteine sind, insbesondere zwei Regionen in der N-terminalen
Doma¨ne und zwei strukturelle Elemente in der katalytischen Doma¨ne. Die Identikation dieser
strukturellen Voraussetzungen tra¨gt essentiell zu unserem Versta¨ndnis der durch Ago-Proteine
vermielten Genrepressions-Aktivita¨t bei.
Ago-Proteine spalten ihre Ziel-RNAs nicht nur. Im Falle teilweiser Komplementarita¨t zwischen
kleiner RNA und Ziel-RNA rekrutieren sie zusa¨tzliche Faktoren, um die Genexpression negativ
zu beeinussen. Vorherrschende Mechanismen sind hierbei translationale Repression und die
Verminderung der mRNA-Stabilita¨t. Angesichts des breiten Spektrums Ago-vermielter Genre-
gulation ist es wichtig zu verstehen, wie diese Proteine selbst reguliert werden. Hier wurden
massenspektrometrische Methoden angewendet, um post-translationale Modikationen, spezi-
ell Phosphorylierungen, von Ago-Proteinen zu untersuchen. Zahlreiche endogene Phosphory-
lierungsstellen von Ago2 und seinen Paralogen wurden detektiert. Darunter benden sich Modi-
kationsstellen, welche in Phosphorylierungs-Clustern organisiert sind. Die im Rahmen dieser
Arbeit gewonnenen Daten sind eine wertvolle Informationsquelle fu¨r zuku¨nige Analysen von
Ago-Proteinen und deren modizierenden Enzymen, welche Einblicke in das Zusammenspiel der
durch kleine RNAs vermielten Genrepression mit Signalwegen geben werden.
Die hier analysierten Phosphorylierungsstellen wurden in endogenen Ago-Proteinen identi-
ziert. Um große Mengen endogener Proteine bereitzustellen, wurde eine neuartige, Peptid-basierte
Aufreinigungsstrategie etabliert.AgoAnity Purication by Peptides (Ago-APP, ’Ago-Anita¨tsrei-
nigung durch Peptide’) basiert auf der Interaktion von Ago-Proteinen mit einem konservier-
vii
ten Bindungpartner, einem Mitglied der GW182-Proteinfamilie. Daher reichert die beschriebene
Aufreinigungsmethode alle vier humanen Ago-Proteine an und kann daru¨ber hinaus Spezies-
unabha¨ngig angewendet werden. Ago-APP stellt ein leistungsfa¨higes Hilfsmiel fu¨r die Charak-
terisierung verschiedener Ago-Komplexe auf den Ebenen von Protein, kleiner RNA und Ziel-
RNA dar.
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1. Introduction
1.1 Argonaute proteins
Argonaute proteins are central components of small RNA-mediated gene silencing. ey associate with
dierent classes of small RNA and mediate gene silencing by various means, including post-transcriptional
as well as transcriptional mechanisms. e small RNA-binding modules are found in many phyla where
they have adopted to specic functions. e number of dierent Argonaute proteins varies between one
in Schizosaccharomyces pombe, ve in Drosophila melanogaster (Drosophila), eight in mammalia, ten in
Arabidopsis thaliana (Arabidopsis), and reaches twenty-six in Caenorhabditis elegans (C. elegans) [1].
Argonaute proteins subdivide into the clades of Ago-like proteins (’Ago proteins’, named aer Arabidopsis
Ago1), PIWI-like proteins (’PIWI proteins’, named aer the Drosophila protein PIWI), and worm-specic
WAGO proteins [2–4].
e members of the rst clade, Ago proteins, are ubiquitously expressed. ey are essential components
of small RNA-guided gene silencing and mediate target repression by mechanisms such as endonucleo-
lytic cleavage or recruitment of additional factors that ultimately aect translation eciency and mRNA
stability [5, 6]. Besides these cytoplasmic functions, Ago proteins are also present in the nucleus, where
they were found to act at transcriptional level [7–9]. Ago-mediated epigenetic silencing is commonly
observed in Schizosaccharomyces pombe, nematodes, and plants [10]. It involves specialized machineries,
that ensure for example small RNA production and DNA methylation [10].
PIWI proteins are predominantly expressed in the germline and protect the genome from mobile genetic
elements through post-transcriptional repression as well as transcriptional silencing of transposon se-
quences [11–13].
Additionally to the Ago and PIWI protein families, C. elegans comprises the third clade of worm-specic
Argonaute proteins, termed ’WAGO’ proteins [2]. ese Argonaute proteins associate for example with
secondary small RNAs that arise from the action of RNA-dependent RNA polymerases and fulll wide-
spread functions [14–16].
Notably, Argonaute proteins are also present in archaea and prokaryotes. Several Argonaute proteins
of these organism associate preferentially with single-stranded DNA rather than with RNA. eir target
molecules can be DNA and RNA [17]. It is currently assumed that such ’ancestral Argonautes’ protect
against mobile genetic elements and represent one of the earliest innate immune strategies [18, 19].
Mammalian Ago proteins associate with microRNAs (miRNAs) or small-interfering RNAs (siRNAs), which
are typically 21–24 nt in length. In contrast, PIWI proteins bind the slightly longer PIWI-interacting RNAs
(piRNAs). e following section describes the biogenesis of these dierent small RNA species.
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1.1.1 Biogenesis of small RNAs
miRNAs and siRNAs. Most miRNAs are encoded by miRNA genes that are transcribed by RNA poly-
merase II [20, 21]. Primary miRNA transcripts (pri-miRNAs) are oen polycistronic and characterized by
hairpin structures, which are anked by single-stranded 3’ and 5’ extensions [22]. e microprocessor
complex, which contains the endonuclease Drosha and its cofactor DGCR8 (DiGeorge Syndrome Critical
Syndrome Region 8), cleaves these transcripts near the basis of the hairpins [23–26]. e resulting miRNA
precursor (pre-miRNA) is then exported to the cytoplasm by exportin 5 [27–29]. ere, the hairpin loop
is removed by the endonuclease Dicer [30, 31], which is associated with the double-stranded (ds) RNA-
binding proteins TRBP (TAR RNA binding protein) and PACT (protein activator of the interferon-induced
protein kinase) [32–34].
siRNAs enter the small RNA biogenesis pathway at the step of Dicer cleavage and typically arise from
long dsRNA [35, 36]. DsRNA can be of exogenous or endogenous sources, for example originating from
viral infections, transposon expression, bidirectional or pseudogene transcription, or from long hairpin
structures [37]. In mammals, long dsRNA is usually targeted by the interferon response system. Here, en-
dogenous siRNAs (endo-siRNAs) have so far only been observed in mouse oocytes [38–40] and embryonic
stem cells [41].
piRNAs. piRNAs are transcribed from distinct piRNA clusters which commonly represent an immense
fundus of diverse transposon sequences [13]. piRNA biogenesis is fundamentally dierent from miRNA or
siRNA biogenesis as it does not involve double-stranded precursors and Dicer processing [42]. For piRNA
production, endonucleolytic cleavage of a single-stranded precursor seems to play a role, but the exact
mechanism is still unknown [43–45]. Noteworthy, piRNA-mediated silencing comprises an amplication
mechanism where the intertwined action of endonucleolytically active PIWI proteins facilitates a directed
response to actively transcribed transposons, known as the ’ping pong cycle’ [46, 47]. Given their role in
antiviral response and protection from mobile genetic elements, the function of mammalian piRNAs does
partly overlap with that of endo-siRNAs [13].
1.1.2 Assembly of the RNA-induced silencing complex
Aer Dicer processing, the resulting dsRNA is loaded into Ago proteins in an energy-dependent process
that requires chaperons [48]. One of the strands (termed ’miRNA*’ or siRNA ’passenger strand’) is re-
moved and degraded. e other strand, the siRNA ’guide strand’, is bound to Ago in an RNA-induced
silencing (RISC) complex and confers specicity for post-transcriptional gene silencing. It was shown
that endonucleolytically active Argonaute proteins can cleave the passenger strand and can therefore ac-
celerate the loading process [49–51]. Additionally, it was proposed that the non-catalytic human Ago1
can cleave passenger strands [52]. However, unwinding and passenger strand removal do not strictly de-
pend on endonucleolytic activity and non-slicing Argonautes are able to load single-stranded RNAs as
well [53, 54]. Due to the high duplex stability of uncleaved siRNAs, loading of non-catalytic Ago proteins
is a slower process [53]. It is not yet known whether duplex unwinding requires an external helicase since
Ago proteins have been reported to play a role in duplex unwinding themselves [55].
1.1.3 The structure of Argonaute proteins
Argonaute proteins consist of four functional domains that are structurally organized within two lobes
[56–62] (Fig. 1.1).
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Figure 1.1: e structure of human Ago2 (A) Domain organization of human Ago2 with the functions
of the PAZ, Mid, and PIWI domains indicated. (B) e structure of human Ago2 (PDB 4W5O, [74]) with
domains colored as in (A). (C) e bound miRNA of 21 nt length is shown in gray. A co-crystallized short
target RNA that pairs from nt 2–9 is depicted in orange.
e Mid domain comprises a binding pocket that can accommodate the 5’ end of the small RNA [63–67].
e 3’ end of the RNA is anchored in the PAZ (Piwi-Agonaute-Zwille) domain [68–70].
e PIWI domain resembles an RNAse-H fold and some Argonautes are indeed able to cleave their targets
endonucleolytically [3]. is slicing activity is thought to rely on the presence of a catalytic triad [56, 71].
Recent structural studies of a yeast Argonaute showed that an additional residue is involved in catalysis,
extending the catalytic center to a tetrade of Asp-Glu-Asp-His [60]. ese residues are conserved in human
Ago proteins [60]. Of the human Ago family members, only Ago2 is able to cleave its targets [72, 73]. e
required catalytic tetrade is also present in human Ago3, suggesting that other protein features aect
cleavage activity as well. Additionally to its endonucleolytic function, the PIWI domain exhibits two
binding pockets for the tryptophan-mediated interaction with GW182 proteins [58].
e N-terminal domain is the region with highest sequence variability of the otherwise very conserved
Ago proteins. ere has not been a characteristically assigned function of the Argonaute N domain for
a long time—until it was suggested to facilitate duplex unwinding and passenger strand removal by its
so-called ’wedging function’ [55].
1.1.4 RNA-binding and endonucleolytic activity
1.1.4.1 Guide and target binding
Ago proteins bind small RNAs via their phosphate-sugar backbone, allowing the bases of the guide RNA
to protrude into the nucleic acid binding channel [58, 65]. Furthermore, the 5’ part of the bound single-
stranded RNA is organized in a preformed A-form helix, ready to accept complementary bases of the target
RNA via Watson-Crick base pairing [58, 65].
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An extrinsic requirement for the cleavage function of Ago proteins is the perfect or near-perfect com-
plementarity of the target RNA. e minimal base pairing requirements have been studied at the DNA-
binding Argonaute protein of ermus thermophilus [75]. Crystallization studies with target DNAs of
dierent lengths showed that base pairing of the guide strand positions 4 to 16 is necessary for target
DNA cleavage. Depending on their number and position, mismatches and bulges are also tolerated. If
mismatches occur between positions 2–8, substrate cleavage is reduced. Mismatches at the cleavage site
abolish slicing function [75]. Additionally to this positional eect, bulges are more likely to be tolerated
in the target strand. is strand has a higher capacity to compensate for non-perfect base pairing because
it does not contact the Ago protein. e only contacts are via Watson-Crick base pairing interactions with
the guide RNA [65].
Human Ago2 is optimized to accommodate partially paired duplexes [74]. Vertebrate miRNAs bind pre-
dominantly to partially complementary target sites. is interaction relies on binding of so-called ’seed
sequences’, i.e. duplex formation of the nucleotides 2 to 8 [76]. Human Ago2 is adapted to recognize these
sites. It comprises a binding pocket for the rst nucleotide of the target RNA, preferentially an adenine.
Outgoing from there, the protein is shaped to meet the minor groove of the guide:target duplex. Beyond
the ninth nucleotide, duplex formation is energetically unfavorable and most likely requires conforma-
tional changes [74].
1.1.4.2 Structural rearrangements during ternary complex formation
A loaded Argonaute does not represent a rigid complex. e two-state model postulates that an Ago-bound
single-stranded nucleic acid is initially anchored at both ends. When duplex formation propagates to the
guide 3’ end, this end is released from the PAZ domain [77]. Several observations support this model and
hint at global rearrangements taking place upon binding of perfectly as well as partially complementary
targets.
Already the modeling of a duplex into one of the rst structurally resolved Argonautes, the Aquifex aeoli-
cus Argonaute, indicated that conformational changes have to take place to accommodate the nucleic acids
[56]. is was expected to include an opening of the nucleic acid binding channel and movement of the
PAZ domain [56]. Both presumptions were experimentally veried by structural studies of the Argonaute
protein from ermus thermophilus [57, 65, 75]. A comparison of a binary complex with a ternary complex
containing a partially complementary target showed that the N and PAZ domains are indeed moved apart
from the Mid-PIWI lobe and ensure opening of the binding channel and accommodation of the double
strand [57, 65]. Furthermore, the guide DNA in a binary complex is kinked between nt 10 and nt 11. Upon
duplex formation, it binds in a dierent trajectory and an unobstructed helix is formed [57, 65]. ese
studies were extended by a detailed structural analysis of cleavage-decient ermus thermophilus Ago
bound to perfectly complementary target RNAs of dierent lengths [75]. In this case, extended duplex
formation releases the guide 3’ end from the PAZ domain [75]. Remarkably, the N domain was observed
to block base pairing of the terminal three bases [75].
Similarly, the guide RNA bound in a human binary Ago complex is also kinked [58]. is kink is in-
troduced by Ile-365 which inserts between guide nucleotides 6 and 7 [58]. Upon binding of a partially
complementary target, the Ile-365-accommodating helix moves and allows for another step of duplex
propagation before it stabilizes the newly-formed conformation [74]. Simultaneously, repositioning of
the PAZ domain and widening of the binding channel seem to be initiated by this helix movement [74].
Additionally to structural studies, kinetic analyses and FRET (Fo¨rster Resonance Energy Transfer) mea-
surements of Ago proteins conrmed the two-state model [78, 79]. FRET experiments used an archaeal
Ago where uorescent dyes were incorporated into dierent positions of the protein and guide DNA. e
strongest FRET shi upon ternary complex formation was detected for a reporter located in the PAZ do-
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main and a guide DNA labeled close to the 3’ end, again favoring a release of the nucleic acid from the
PAZ domain upon target binding [78].
Structural studies of Argonaute from the yeast Kluyveromyces polysporus identied a fourth catalytic
residue necessary for target cleavage [60]. It is located on a so-called ’glutamate nger’ which can
adopt an active (’plugged-in’) and an inactive (’plugged-out’) conformation. e comparison of cleavage-
incompatible and cleavage-compatible Ago conformations in ermus thermophilus suggested that a 3’
guide release from the PAZ domain triggers several loop rearrangements which lead to the insertion of the
glutamate nger into the catalytic center [80]. However, the inactive conformation has not been identied
in other eukaryotic Agos [60] and it is still unclear if this region is subject to structural rearrangements
in human Ago2 [17].
1.1.5 Individual functions of human Ago proteins
1.1.5.1 The role of Argonaute cleavage activity in mammalia
In mammals, perfectly complementary miRNA targets do rarely exist. Considering the possibility to ac-
cept certain helical imperfections, target cleavage might still have an impact on miRNA-mediated gene
regulation. Ago-mediated endonucleolytic activity has indeed been observed, but it occurs only for few
targets [81–85]. More than miRNAs, endo-siRNAs depend on target slicing. Mammalian endo-siRNAs
have so far only been detected in mouse oocytes and embryonic stem cells, where they are suggested to
act as part of an ancient immunity system [38–41]. e RNAi machineries of Drosophila and C. elegans
are functionally separated and can therefore be targeted selectively. In these model organisms, the inac-
tivation of siRNA-mediated repression shows no phenotypic eects [86–89]. Taken together, endogenous
target cleavage contributes only lile to mammalian miRNA-mediated gene regulation.
However, exogenously applied siRNAs are of high interest for drug development and represent a widely
used tool in molecular biology. siRNA-mediated knockdowns depend on the catalytic activity of Ago2,
which is shown by the fact that Ago2-depleted mouse embryonic broblasts are not sensitive to RNAi
treatment [73]. Still, non-catalytic Ago proteins have also been reported to contribute to siRNA-mediated
knockdowns [90].
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Figure 1.2:e function of Ago2 cleavage activity. ree processes that depend on endonucleolytic ac-
tivity of human Ago2: target cleavage (A), passenger strand cleavage (B), and endonucleolytic processing
of non-canonical miRNAs (C). e target mRNA is designated by its cap and poly(A) tail.
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Additionally, Ago2 cleaves perfectly paired passenger strands like it cleaves perfectly paired targets [49–
51], thereby facilitating ecient passenger strand removal and RISC formation [53].
If Ago2 does usually not cleave miRNA targets, why is its endonucleolytic activity conserved? An answer
to this question is provided by engineered mice, which express non-slicing Ago2. ese animals show
erythropoietic defects and lack one specic miRNA, which regulates the dierentiation of erythroid lin-
eages [91]. miR-451 does not depend on Dicer processing, but is bound to Ago2, sliced, and trimmed by
additional factors to yield a mature miRNA [91–96].
Taken together, the catalytic function of Ago2 plays a role in cleavage-mediated silencing of target RNAs,
during RISC assembly, and during processing of non-canonical miRNAs (Fig. 1.2).
1.1.5.2 Paralogue-specific expression defines Ago protein function
Erythropoietic defects were also observed when Ago2 was specically deleted from bone marrow (and
therefore from lymphoid and erythroid lineages) [97]. Interestingly, this phenotype is independent of the
catalytic activity of Ago2 [97], indicating a specic role of Ago2 in its ’non-slicing’ function. A complete
knockout of Ago2 is embryonic lethal, suggesting that this protein is indispensable for embryonic devel-
opment [73, 98]. In contrast, Ago1, Ago3, and Ago4 knockout mice and even combinatorial Ago1/Ago3
and Ago1/Ago4 knockout mice are viable [99]. Whereas a combination of Ago1 and Ago3 was reported to
play a role in u resistance [99], male Ago4 knockout mice display fertility defects and meiotic alterations
[100]. In particular, sex chromosome inactivation is perturbed in these mice and prophase I is induced
prematurely [100].
Importantly, any Ago protein can mediate miRNA-mediated repression in mouse embryonic stem cells
depleted of Ago1–4, indicating that mammalian Agos function redundantly in the miRNA pathway [101].
In line with that, cross-complementing expression changes (e.g. increased Ago1 expression upon Ago2
depletion) have been observed in studies that investigated Ago knockouts [100, 102]. However, assuming
that human Ago proteins function redundantly, specic functions could still be conferred by the selective
loading of miRNAs, termed ’sorting’.
1.1.5.3 Sorting of small RNAs into Ago proteins
Depending on the organism, small RNA sorting exists at dierent degrees of complexity. For example, a
very strict sorting system in Drosophila targets miRNAs to Ago1 and siRNAs to Ago2. Discrimination is
already applied during small RNA biogenesis, when the structurally dierent precursors are loaded into
two dierent Dicer complexes [103, 104].
Arabidopsis comprises a complex processing and silencing machinery, including four Dicer and ten Ago
proteins. Here, a substantial part of sorting is mediated by the identity of the small RNA 5’ nucleotide
[105].
In contrast, human Ago proteins interact with only one Dicer paralogue [4]. All human Ago proteins
bind miRNAs and siRNAs [72, 73]. e individual Agos bind a similar spectrum of miRNAs [95, 106] and
targets [106, 107], as identied by dierent sequencing approaches. Interestingly, aer combined deple-
tion of Ago1 and Ago2 in mouse skin, Ago3 associates with a similar set of miRNAs as Ago1 and Ago2
do in wild type samples [102]. A special case of sorting exists for miR-451, whose processing depends on
an endonucleolytically active Ago protein. Pre-miR-451 is loaded to all human Ago proteins, but mature
miR-451 is exclusively associated with human Ago2 [93, 94].
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Taken together, there is lile evidence for a role of miRNA sorting in mammals. However, among the
human Ago proteins, Ago2 is clearly in a special position, but this is only partly aributable to its endonu-
cleolytic activity. A large part of Ago2-related eects is probably related to its expression determinants.
1.1.6 Expression levels of human Ago1-4
So far, most of the studies that addressed Ago1–4 expression levels relied on mRNA-based techniques and
utilized semiquantitative or quantitative PCR approaches [72, 108–111]. Ago1–3 transcripts show a rather
ubiquitous and overlapping expression in dierent tissues [72, 108, 109]. A comparison of expression levels
reveals that in general Ago2 is most abundant, followed by Ago1, Ago3, and Ago4 [111]. Interestingly,
the otherwise very weakly expressed Ago4 is enriched in whole testis as well as in certain cell types
corresponding to dierent stages of spermatogenesis [110].
At protein level, three dierent approaches have been used for Ago quantication.
First, the four human Ago proteins were immunopuried by monoclonal antibodies and mass-spectro-
metrically analyzed [53]. is strategy presupposes that the used antibodies have similar eciencies and
deplete comparable ratios of the individual Agos from the cellular extract. Such a condition is unlikely
and the estimated ratios of 24:60:14:1.2 (Ago1:Ago2:Ago3:Ago4, measured in HEK 293T cells) should be
interpreted carefully.
In another approach, shotgun proteomics was applied and Ago1–3 contents were quantied by the number
of unique, paralogue-specic peptides that were detected [102]. Using this technique, ratios of 22:80:22
(Ago1:Ago2:Ago3, measured in a human melanoma cell line) were reported [102]. However, mammalian
Agos are very similar at amino acid sequence level. erefore, Ago peptides can oen not be assigned
to an Ago paralogue in mass-spectrometric measurements. Consequently, these non-assignable peptides
introduce strong uncertainty.
Finally, a pulldown experiment conducted to conrm Ago binding to a specic TNRC6B fragment iden-
tied all human Agos in the ratios 26:61:12:1 (Ago1:Ago2:Ago3:Ago4, measured in HeLa cells) [112]. e
interpretation of these mass-spectrometric data entailed similar uncertainties, esp. in terms of peptide
assignment and mass-spectrometric intensities. However, the applied enrichment step for Ago proteins
represents a valuable basis for future analysis.
A puzzling aspect of Ago expression is the codon usage in their mRNAs, especially the occurrence of
more rare codons in Ago3 and Ago4 [111]. It is not known whether this intrinsic eect is due to the
redundancy of the highly similar Ago proteins and Ago3/Ago4 progressively loosing importance, or if it
serves a certain purpose and is required to ne-tune Ago expression [111].
1.1.6.1 Ago protein and small RNA levels are interdependent
Several studies conducted in dierent experimental systems show that miRNA and Ago levels are interde-
pendent (Fig. 1.3). On the one hand, Ago protein levels depend on the presence of small RNAs. Unloaded
Ago is not stable and is subjected to degradation [114, 115]. On the other hand, small RNAs depend on the
presence of Ago proteins [116, 117]. Consequently, Ago depletion reduces the levels of mature miRNAs in
several organisms [97, 118–120] and Ago overexpression increases miRNA levels [120, 121]. It is assumed
that this interplay between Ago and miRNA levels depends on an Ago function during miRNA biogenesis,
most likely during product release and loading aer Dicer processing of the pre-miRNA [97, 122]. Tipping
the sensitive equilibrium of a system with low Ago expression can have unexpected consequences, e.g. a
release of endogenous target repression upon siRNA treatment [122, 123].
8 1. INTRODUCTION
proteasomal 
degradation
Ub 
Ub 
Ub Ub 
Ub 
Ago Ago Ago
1   :   1
Dicer
exonucleolytic
degradation?
active 
RISC
active 
RISC
active 
RISC
Dicer Dicer
Figure 1.3:e interdependence of Ago and small RNA levels. Unloaded Ago proteins are unstable and
subjected to degradation (le side), whereas small RNA levels depend on the presence of Ago proteins
(right side). Partially adapted from [113].
One study aempted to determine the exact miRNA and Ago copy numbers per cell [124]. In contrast to the
observed interdependency, the authors concluded that there is an about 13-fold excess of miRNA molecules
over Ago molecules [124]. Another study quantitatively compared the miRNA content of immunopuried
Ago2 with that of total lysate, hypothesizing that a large part of miRNAs is not RISC-associated [125].
Moreover, a third study reported that miRNAs associate with Ago proteins to dierent extents [126].
ese reports suggest that not all miRNAs are bound to Ago [124–126].
1.1.6.2 Dynamic changes of Ago protein expression
Importantly, the described studies represent snapshots of Ago1–4 protein expression. Several observations
point at Ago expression being regulated time-dependently and tissue-specically. For example, total Ago
levels can change as part of cellular reprogramming events. is has been observed during the activation of
T cells, when a major part of the total Ago pool is subjected to proteasomal degradation, thus reseing the
miRNA machinery and allowing to substitute a large portion of translationally repressed targets [127]. A
more specic readjustment of the Ago protein levels has been observed during mouse brain development,
where the initially high Ago1 levels decrease and adapt to the lower levels of Ago2 [121]. Since Ago2
exhibits 3’ trimming activity towards mature miRNAs, a strongly altered Ago1:Ago2 ratio might ultimately
aect miRNA isoform identity, target binding, and target repression [121].
1.2 Argonaute and GW182 proteins
Mammalian miRNA-mediated gene silencing depends only to minor parts on endonucleolytic cleavage.
e major part of repression is based on translational inhibition and mRNA destabilization. To accom-
plish these functions, Ago proteins recruit additional eector complexes. erefore, Ago proteins directly
interact with GW182 proteins, which are termed TNRC6A, B, and C (trinucleotide repeat-containing pro-
tein 6 A, B, and C) in humans [128, 129]. ese proteins are core components of the eector complexes
and are required for miRNA-mediated repression in metazoan organisms [128, 130–133]. Importantly,
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GW182 proteins alone can silence reporter mRNAs when they are articially bound to them [134]. e
exact mechanism of silencing is still under investigation, but it is becoming clear that it involves both
mechanisms of target destabilization and translational repression [6].
1.2.1 Mechanisms of GW182-mediated repression
For miRNA-mediated gene silencing, deadenylation of the target RNA plays a crucial role [134–136].
GW182 proteins recruit the deadenylation complexes CCR4-NOT and PAN2-PAN3 [6, 137–139]. Besides
deadenylation, decapping and 5’–3’ decay also contribute to target destabilization [6]. Importantly, several
translation factors were reported to dissociate from decapped and/or deadenylated target RNAs, suggest-
ing that target destabilization and translational inhibition are coupled [140].
However, deadenylation- and decapping-independent repression has also been observed [138, 141] and
such active mechanisms of translational repression are currently discussed. One line of evidence is pro-
vided by the interaction of GW182 proteins with the poly(A) binding protein (PABP) [142, 143]. One
of the rst models for GW182-mediated translational repression suggested that GW182 and eIF4G (a cap-
binding translation initiation factor) compete for PABP binding [142, 143]. GW182 binding to PABP would
therefore prevent closed-loop formation, which stimulates translation [142, 143]. However, current mod-
els favor a positive eect of the poly(A) tail and PABP on the association of RISC with the target mRNA
[144]. Aer target binding, PABP dissociates from the complex, which simultaneously decreases trans-
lation eciency [140, 144]. Furthermore, it was recently shown that RISC induces the dissociation of
eIF4AI and eIF4AII from the mRNA, thereby preventing translation initiation [145–147]. Also recently,
the translational repressor and decapping activator DDX6 was reported to bind to the CCR4-NOT complex
[148, 149]. Altogether, the outlined mechanisms establish important links between CCR4-NOT recruit-
ment and translational repression.
It has been a long-lasting debate if silencing is mediated by translational repression, destabilization of the
target RNA, or a combination of both mechanisms. e contribution of these mechanisms was studied
at reporter constructs [150, 151] and endogenous targets [152, 153]. ese studies suggested that trans-
lational repression dominates over destabilization at the beginning of a repression event and that target
destabilization prevails aer a while [150–153]. Importantly, neither of the two repression modes can be
ruled out and future research will reveal how they are used and if they are mechanistically coupled.
1.2.2 The molecular basis of tryptophan-mediated GW182 interactions
GW182 proteins are characterized by a C-terminal silencing domain that comprises several interaction
motifs such as an ubiquitin-associated (UBA)-like domain, a glutamine (Q)-rich region, RNA recognition
motifs (RRMs), or a poly(A) binding motif (PAM2). Apart from these motifs, GW182 proteins are largely
unstructured proteins that contain several regions with multiple glycine/tryptophan repeats. ese re-
gions occur throughout the protein with most of them being present in the N-terminal part. Here, the
GW motifs are important for Ago binding and up to three Ago binding motifs have been identied in this
region [154–157].
To further analyze the molecular mechanism of Ago binding, a recent study investigated the N-terminal,
GW-rich region by means of a peptide array [112]. ree binding hot spots were identied, one of which
had been described before [112, 129]. is Ago-binding peptide (TNRC6B 599-683) was characterized in
detail. e GW peptide is unstructured and contains ve tryptophans. Mutagenesis, nuclear magnetic
resonance (NMR) titration experiments, and crosslinking experiments showed that Ago binding is medi-
ated by two of these residues, with W623 contributing the main part and W634 further enhancing binding
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anity [112]. Importantly, not all tryptophan-containing peptides that were used in the peptide array
conducted by Pfa et al. were able to bind Ago. e comparison of positive binders suggested that trypto-
phan spacing denes Ago binding [112]. is is in line with the distinct spacing of two tryptophan binding
pockets that were identied in structural studies of human Ago2 [58].
Tryptophan-mediated interactions of GW182 proteins are not only essential for Ago binding, but also for
interaction with the deadenylation complexes CCR4-NOT [138, 139] and PAN2-PAN3 [138, 158]. Binding
of these complexes depends on an additive eect of several tryptophan residues [138]. Interestingly, even
an unrelated peptide with engineered Trp-containing motifs was shown to mediate the interaction with
CCR4-NOT, indicating that the exact sequence context is less important than the presence of tryptophans
[138]. Similar to human Ago2, structural studies revealed also the presence of two tryptophan binding
pockets in CNOT9, the main GW182-interacting subunit of CCR4-NOT [148, 149]. In contrast, only one
tryptophan binding pocket is suggested to mediate the interaction of GW182 and PAN3 [158]. e pocket
is located at the dimerization interface of homodimerized PAN3. Consequently, binding of the TNRC6C
silencing domain was reported to depend on the dimerization of PAN3 [158]. Interestingly, this binding
mode would provide the possibility to regulate the association of GW182 and PAN3 by dimerization of
PAN3 [158].
Taken together, multiple interactions of GW182 proteins are mediated by tryptophans. Protein association
can be determined by binding of one or multiple tryptophan residues, an inuence of anking residues,
and/or an inuence of tryptophan spacing. With that, GW182 are important binding platforms that con-
nect Ago proteins to a complex machinery that mediates deadenylation and translational repression.
1.3 Regulation of small RNA-guided gene silencing by
post-translational modifications
Small RNA-guided gene silencing regulates numerous cellular processes. To facilitate adequate responses,
the silencing machinery itself is subject to regulation, as already exemplied by the interdependence of
Ago protein and small RNA expression (section 1.1.6). Another layer of regulation is added by post-
translational modications [4]. e following section covers post-translational modications that aect
miRNA biogenesis and function. First, it gives a short overview on known modications of components
that are involved in the biogenesis of small RNAs. ereaer, phosphorylation of Argonaute proteins is
covered in detail.
1.3.1 Post-translational modifications of miRNA biogenesis components
Drosha, the endonuclease that initiates miRNA biogenesis, is a nuclear protein. Its localization is ensured
by phosphorylation of two serine residues in its N-terminal region and depends on GSK3β (glycogen
synthase kinase 3β) [159, 160]. Furthermore, acetylation and ubiquitination occur in the same region and
were reported to aect protein stability [161].
Another miRNA biogenesis factor, the Dicer binding partner TRBP, is also phosphorylated at several sites
[162]. ese modications were found to increase stability of the Dicer-TRBP complex, resulting in en-
hanced miRNA generation and miRNA-mediated repression. TRBP is phosphorylated by the MKK1/Erk
pathway and upon pathway activation, growth-promoting miRNAs seem to be selectively upregulated
[162]. However, it is not clear how this additional level of regulation is achieved.
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1.3.2 Post-translational modifications of Argonaute proteins
Argonaute proteins can be post-translationally modied in many ways, e.g. by phosphorylation, ubiqui-
tination, hydroxylation, and methylation.
PIWI proteins of Drosophila, Xenopus laevis, and mouse are methylated in arginine-glycine (RG)-rich
regions at their N-termini [163–166]. It was reported that this symmetric dimethyl arginine (sDMA) mod-
ication of arginine residues depends on protein methyltransferase 5 (PRMT5) [164]. e modication
is necessary for the interaction with Tudor-domain containing proteins. Hence, it aects fundamental
PIWI-specic functions such as transposon silencing, PIWI protein localization, or the identity of the
small RNAs that are loaded to the proteins [163–166].
Several post-translational modications have been identied for human Ago proteins. Whereas ubiquiti-
nation and sumoylation decrease protein stability [167, 168], hydroxylation of Ago2 positively regulates
protein stability [169] (Fig. 1.4).
Ago2 hydroxylation at P700 depends on type I collagen prolyl-4-hydroxylase [C-P4H(I)] and has been
validated by mass-spectrometric analysis of the endogenous protein [169]. C-P4H(I) is activated under
hypoxic conditions when also Ago2 stabilization in pulmonary artery smooth muscle cells is observed,
concomitant with positive eects on the expression of certain miRNAs and RISC activity in general [170].
In contrast, Ago proteins are destabilized by ubiquitination. Until now, the only described E3 ubiquitin lig-
ase interacting with Ago is mLin41 (also known as Trim71) [167]. Ago2 ubiquitination has been observed
in mouse embryonic stem cells [167], but not in another experimental system using neural progenitor
cells [171]. It remains to be seen if mLin41/Trim71 aect Ago levels by ubiquitination or if these pro-
teins predominantly act through dierent mechanisms such as translational repression or complemen-
tation of miRNA-mediated repression [172, 173]. However, ubiquitination is involved in Ago turnover
[114, 127, 174], although autophagy mechanisms have also been reported [115, 175].
1.3.2.1 Phosphorylation of human Ago proteins
Due to its dynamic nature and its strong involvement in signaling pathways, phosphorylation is the most
investigated post-translational modication. Several sites of Ago2 have been reported to be phosphory-
lated and aect for example protein stability or small RNA binding (Fig. 1.4) [4, 176]. Among them is
S387. Phosphorylation of this site has been shown to promote localization of Ago2 to processing bodies,
cytoplasmic foci involved in RNA turnover [177]. S387 phosphorylation depends on activation of the p38
MAPK pathway, in particular on MAPKAPK2 [177]. Another study identied the kinase Akt3 and hy-
pothesized that S387 phosphorylation decreases the amount of target cleavage compared to translational
repression [178]. Irrespective of its cellular function, phosphorylation of S387 seems to be a common
post-translational modication which is present under standard growth conditions and can be increased
in response to cellular stresses [177].
Several phosphorylated sites were identied by mass-spectrometric analysis of overexpressed and im-
munopuried Ago2 [179]. Remarkably, the study by Ru¨del et al. included already known modication
sites (e.g. pS387) as well as sites that were conrmed in later investigations (e.g. pY393). Simultaneously,
this work identied Y529 as a modication site and showed that phosphorylation at this position inter-
feres with small RNA binding [179]. e same site was characterized in another study, which focused on
activated mammalian macrophages [180]. Here, phosphorylation of Y529 was suggested to facilitate the
dynamic exchange of Ago2-bound miRNAs, consequently relieving the repression of certain targets and
enabling the expression of proinammatory genes [180].
Finally, phosphorylation of Y393 occurs under hypoxic conditions and depends on the kinase activity of
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Figure 1.4: Post-translationalmodications of humanAgo2. Summary of ubiquitination, hydroxylation,
and phosphorylation events that aect human Ago2. Proposed functions of the dierent modications and
modifying enzymes are indicated. Adapted from [4, 113].
EGFR [181]. Phosphorylation of this residue decreases the interaction with Dicer and aects matura-
tion and loading of certain miRNAs termed ’mHESM’ (miRNAs regulated by hypoxia-dependent EGFR-
suppressed maturation) [181]. ese miRNAs have tumor-suppressive function and their precursors have
a large loop structure in common, suggesting that this specic feature decides on dierential maturation
and loading ability in a complex of Ago2 (pY393) and Dicer. Importantly, Y393 phosphorylation is enriched
in hypoxic tumor areas and correlates negatively with survival rates of breast cancer patients [181].
Table 1.1 gives an overview on the described phosphorylation sites, their proposed function, and on the
methods used to detect these modications.
On the structural level, the inuence of the described modication sites cannot be explained to full extent.
Fig. 1.5 illustrates the position of the known and characterized phosphorylation sites. S387 and Y393 are
located in the second linker region (L2), which is in close proximity to the N-terminal domain of Ago2
(Fig. 1.5 A). Since Dicer interaction is decreased in Y393 phospho-mimicking mutants, this region was
suggested to be part of the binding surface. However, Dicer is known to bind to a particular region in
the Ago PIWI domain termed ’PIWI box’ [182] and it is structurally not clear how the Y393 modication
aects this interaction, especially how it selectively inhibits maturation of longer loop precursors [181].
Y529 is located within the 5’ binding pocket formed by the Mid domain (Fig. 1.5 B). e 5’ nucleotide of
the bound small RNA stacks to Y529. Since the hydroxyl group of this amino acid is oriented towards
the 5’ phosphate of the rst guide nucleotide, a phosphorylation of this residue was suggested to induce
electrostatic repulsion and thus prevent small RNA binding [179].
S387 and Y393 are located at the protein surface and would therefore be easily accessible by a kinase.
However, Y529 is buried inside the protein in a pocket usually occupied with the small RNA (Fig. 1.5 A). It
is questionable if this residue can be accessed by any kinase or if alternative phosphorylation mechanisms
exist [179].
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Table 1.1: Overview on known phosphorylated sites of Ago2. e position of the phosphorylated site, its
proposed function, and the used detection methods are summarized.
site ref. proposed function PTM identication and validation
pS387 [177] localization IP of FLAG/HA-Ago2 and MS analysis
in vitro phosphorylation assay
pS387-specic antibody
pS387 [179] (localization) IP of FLAG/HA-Ago2 and MS analysis
pS387 [178] switch from target cleavage to
translational repression
pS387-specic antibody
pY393 [179] unknown IP of FLAG/HA-Ago2 and MS analysis
pY393 [181] Dicer binding,
miRNA processing
IP of FLAG-Ago2 and MS analysis
in vitro kinase assays
pY393-specic antibody
pY529 [179] miRNA binding IP of FLAG/HA-Ago2 and MS analysis
IP of endogenous Ago2 with pY-specic antibody
pY529 [180] (miRNA binding) IP with pY-specic antibody
phospho-mimicking and non-phosphorylatable
mutants
pS253, [179] unknown IP of FLAG/HA-Ago2 and MS analysis
pT303,
pT307,
pS798
1.3.2.2 Modifying enzymes and signaling pathways
ere is an increasing number of studies that link post-translational modications to cellular cues, sig-
naling, and disease. For example, a connection between RAS-induced senescence, Ago2, and the miRNA
machinery has been identied recently [183]. Here, the cysteine-containing catalytic center of protein ty-
rosine phosphatase 1B (PTP1B) was shown to be oxidized by RASG12V-induced ROS signaling. is results
in inactivation of the phosphatase and specic enrichment of Y393-phosphorylated Ago2. Similar to the
work of Shen et al. [181], this study could also show decreased Dicer interaction and miRNA binding of
a pY393-mimicking mutant [183]. Among the less expressed miRNAs are several miRNAs targeting the
oncogene p21. e authors suggest that constitutive pY393 phosphorylation results in an altered miRNA
expression prole and de-repression of the senescence-mediating p21, which would provide a link be-
tween ROS signaling and senescence [183]. Interestingly, this pathway does not involve activation of a
kinase, but inactivation of a phosphatase.
Signaling pathways aect the small RNA machinery not only by direct modication of its components. As
an example, the Hippo pathway accounts for elevated miRNA levels in response to increased cell density
via a rather indirect mechanism [184]. Hippo signaling is inactive at low cell densities. A cofactor of the
Microprocessor complex, p72, interacts then with YAP (Yes-associated protein), which is retained in the
nucleus. Maturation of p72-responsive miRNAs is inecient under these conditions. Aer pathway acti-
vation and phosphorylation, YAP localizes to the cytoplasm. Hence, p72 is accessible for Microprocessor
accessory function and miRNA processing is promoted [184]. Importantly, the interaction of p72 and YAP
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Figure 1.5: Localization of known phosphorylation sites of Ago2 (A) e position of known phospho-
rylation sites is shown in the structure of human Ago2 (PDB IP 4OLA, [58]). (B) Close-up view of the 5’
binding pocket of human Ago2. Y529 is shown in red and the bound guide RNA is shown in blue.
is increased in YAP-dependent tumors.
Interestingly, Ago degradation during T cell activation depends on PI3K/mTOR signaling, suggesting a
functional link between the phosphorylation and ubiquitination machineries [127].
Hypoxia and high cell density are extreme conditions. Numerous mechanisms may exist to adapt cells
to these and other conditions, be it by ne-tuning one of the pathways described here or by exploiting
completely dierent, yet uncharacterized post-translational modications.
In addition, most studies so far focused on phosphorylation of human Ago2. Hardly anything is known
about its paralogues Ago1, Ago3, and Ago4. Do these proteins underly similar regulation mechanisms?
Or would a paralogue-specic modication confer specic functions to one of the Ago family members?
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Aim of this thesis
Ago proteins take a central role in post-transcriptional gene silencing. ey associate with small non-
coding RNAs, which provide them with specicity and guide them to target RNAs. Some Ago proteins
are endonucleolytically active and can cleave their targets. Furthermore, Ago proteins recruit additional
factors and thereby mediate translational repression and target destabilization.
One requirement for Ago cleavage function is the presence of a dened catalytic tetrade in the active
center of the proteins. Still, the presence of these four residues is not always sucient to mediate en-
donucleolytic cleavage, as exemplied by human Ago3. By a detailed analysis of the inactive human Ago
proteins (Ago1, Ago3, and Ago4), this thesis aimed at identifying additional requirements, which aect
the endonucleolytic function of human Ago proteins.
Since Ago proteins are part of a powerful regulation machinery, it is essential to understand how these
proteins are regulated themselves. Regulation is oen achieved by post-translational modications and
also human Ago proteins are post-translationally modied. However, only few sites are known and most
of these were detected using overexpressed Ago proteins. erefore, a second focus of this thesis is the
mass-spectrometric identication of endogenous post-translational modications, in particular the identi-
cation of phosphorylations. Potential phosphorylation sites should be subjected to a rst characterization
in terms of accessibility, cross-species conservation, and functionality.
e mass-spectrometric analysis of post-translational modications requires large amounts of material,
which can hardly be provided by antibody-based approaches. erefore, a beer tool for the isolation of
Ago proteins was to be established and characterized.

2. Results
2.1 Analysis of human Argonaute cleavage activity
Of the human Ago protein family members, Ago2 is the only protein with slicer activity. It is known
that this endonucleolytic activity resides in the PIWI domain, which resembles an RNase H-like fold. It
has also been shown that three catalytic residues (DDH) within this domain determine cleavage activity.
Interestingly, a fourth catalytic residue was identied and extends the catalytic center to a tetrad of DEDH.
Although these residues are present in the Ago3 PIWI domain, Ago3 is not an endonuclease. Here, minimal
regions of human Ago3, Ago1, and Ago4 were substituted by the respective Ago2 sequences to investigate
additional factors that determine cleavage activity.
2.1.1 The Argonaute N domain aects cleavage activity
First, chimeras of Ago2 and Ago3 were designed and tested for slicer activity. erefore, FLAG/HA-tagged
Ago mutants were expressed in HEK 293T cells, subjected to anα-FLAG immunoprecipitation (IP), and in-
cubated with a radiolabeled target RNA fully complementary to endogenous miR-19b. In a rst approach,
increasing portions of Ago3 were fused to Ago2 and tested in the described in vitro assay (Fig. 2.1 A).
Interestingly, a chimera containing the Ago3 PIWI domain is able to cleave the target RNA (Fig. 2.1 B,
lane 7), indicating that the factor inactivating Ago3 slicing function is located beyond the PIWI domain.
Analysis of the other chimeras showed that—although MutB and MutC have weaker cleavage activities—
even a mutant containing only the rst 170 N-terminal amino acids of Ago2 is able to cleave the target
RNA (Fig. 2.1 B, lane 12).
e amino acid sequences of human Ago1–4 are generally very similar, but their N-terminal regions show
relatively high divergence. Ago3 diers from the other Agos at two main sites: rst, the very N-terminal
part of Ago3 is shorter than that of Ago1 or Ago2. Second, there is an Ago3-specic insertion of eight
amino acids (Fig. 2.2A). To further narrow down sequence elements that aect Ago slicer activity, dierent
Ago3 N-terminal mutants were designed and tested (Fig. 2.2B). Adjustment of the very N-terminal part to
the sequence present in Ago2 did not aect cleavage function (Fig. 2.2). A combination of this mutant with
a deletion of the Ago3-specic insertion did also not aect endonucleolytic activity. In the next step, both
regions were extended. is systematic analysis revealed that amino acids 1-64 and 137-160 facilitate Ago3
cleavage function when substituted by the according Ago2 sequence (Fig. 2.2). Importantly, adjustment
of only the rst region does not suce to render Ago3 cleavage-active (data not shown).
Hence, Ago cleavage function is not only dened by the PIWI domain, which harbors the catalytic center.
Two short sequence elements in the N domains of human Ago2 and Ago3 are implicated in slicing as well.
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Figure 2.1:e Ago3 N domain aects cleavage function. (A) An increasing portion of Ago3 was fused
to Ago2 to identify regions important for slicer function. General domain organization, location of the
catalytic residues, and Ago2/Ago3 wild type features are shown on top. (B) FLAG/HA-tagged Ago1-3
wild type constructs and Ago2-3 chimeras were expressed in HEK 293T cells, immunoprecipitated, and
assayed for slicer function using a radioactively labeled target RNA complementary to the co-precipitating
endogenous miR-19b. ’T1’ indicates a partial RNAse T1 digest of the cap-labeled target RNA. e black
bar to the le represents the region of the target RNA complementary to miR-19b. e cleavage product
is indicated by an arrow. A part of the immunoprecipitated proteins was used for Western Bloing to
ensure equal transfection and IP eciency.
2.1.2 Cluster 2 is an additional PIWI domain feature that defines
cleavage activity
In contrast to Ago3, Ago1 does not comprise a complete catalytic tetrade in its PIWI domain (Fig. 2.3 A, B).
Surprisingly, introduction of the fourth catalytic residue did not activate Ago1 cleavage function (Fig. 2.3 C,
lane 3). To investigate the Ago1 PIWI domain independently of the other Ago1 domains, it was fused to
the Ago2 N-PAZ-Mid module which has been shown to support slicer function (Fig. 2.1, Ago2–3 PIWI).
Adjustment of the catalytic tetrade in this Ago2–1 chimera did also not aect slicer activity, suggesting
that other features in the Ago1 PIWI domain interfere with slicing (Fig. 2.3 C, lane 5). e alignment of
the Ago1–4 PIWI domains revealed two regions that dier from the sequences present in the cleavage-
competent PIWI domains of Ago2 and Ago3, cluster 1 and cluster 2 (Fig. 2.3 A, gray). Interestingly, these
regions either contain or are in close proximity to one of the catalytic residues E635 and D667 in Ago1.
Whereas changing cluster 1 to the sequence present in Ago2 did not aect the chimera’s cleavage activity,
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Figure 2.2: Cleavage activity of Ago3 N-terminal mutants. (A) Alignment of the N domains of Ago1–4.
Chimeric borders are indicated by numbers according to the Ago2 sequence. Substituted sequences are
shown in red. Minimal sequence elements dening cleavage function are shown in bold red. (B) Schematic
overview of Ago3 mutants with N-terminal deletions and substitutions. Only the N-terminal parts of the
protein chimeras are shown. (C) Ago3 N-terminal mutants were tested for slicer activity as described in
Fig. 2.1.
alteration of cluster 2 restored it to wild type levels (Fig. 2.3).
2.1.3 An additional insertion in the Ago4 PIWI domain prevents slicing
function
Ago4 shows the strongest sequence variation among the highly conserved human Agos. Instead of the
catalytic tetrade DEDH, Ago4 comprises the residues DEGR (Fig. 2.4 A, B). To test whether this is the only
feature obstructing its slicer activity, the Ago4 PIWI domain was fused to the N-PAZ-Mid module of Ago2
and the catalytic tetrad was restored (Fig. 2.4 B). Introduction of the catalytic residues did not activate
Ago4 PIWI slicer function (Fig. 2.4 C, lane 2). At amino acid sequence level, the Ago4 PIWI domain diers
from the PIWI domain of Ago2 at two more sites: rst, Ago4 harbors a ten amino acids long insertion
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described in Fig. 2.1
that is not present in the other Agos. Second, the Ago4 sequence at cluster 2 (which has been identied
to aect Ago1 slicer function) diers also from Ago2 (Fig. 2.4 A). Deletion of the Ago4-specic insertion
or adjustment of the cluster 2 sequence alone did not activate the Ago4 PIWI domain (Fig. 2.4 C, lanes 3
and 4). When both alterations were combined, cleavage activity of the Ago4 PIWI domain reached Ago2
wild type levels (Fig. 2.4 C, lane 5).
To investigate how cluster 2 and the Ago4-specic insertion might aect slicer function, homology models
of Ago1 and Ago4 were built on the basis of the human Ago structures published at that respective time.
For the Ago1 homology model, this included only structural information on Ago2, but Ago1 and Ago2
structures could be used for Ago4 homology modeling [58, 59, 61, 62].
A comparison of the catalytic centers of both proteins shows that Ago1 comprises a shortened helix at a
position where Ago2 is characterized by a kinked helix (Fig. 2.5 A, cluster 2 of Ago1 shown in orange).
is was also veried by secondary structure content analysis by means of the algorithm DSSP (Dene
Secondary Structure of Proteins), which uses structural information of a protein or homology model to
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Figure 2.4: Cleavage activity of the Ago4 PIWI domain. (A) Partial alignment of the Ago1–4 PIWI
domains. e positions of catalytic residues are indicated by black triangles. Ago4 comprises a specic
insertion of ten amino acids, highlighted in orange. e variant region corresponding to cluster 2 of Ago1
is boxed, varying amino acids are shown in gray. (B) Schematic overview of the Ago4 PIWI mutants. Only
the PIWI-containing parts of the proteins are shown. Deletions are indicated by light orange color. (C) A
cleavage assay of the Ago4 PIWI mutants was conducted as described in Fig. 2.1
assign secondary structure [185]1. Since cluster 2 is located close to the catalytic residue D669 (D667 in
Ago1), it might be possible that secondary structure changes in that region induce a mis-alignment of the
catalytic center and thus prevent target cleavage.
Additionally to cluster 2, the Ago4 PIWI domain bears a specic insertion of ten amino acids length that
obstructs slicer function (Fig. 2.4). In this case, the homology model reveals that the insertion forms a loop
adjacent to E637 (E629 in Ago4) (Fig. 2.5 B). is residue has been identied to extend the catalytic triad
to a tetrade in Ago of the yeast Kluyveromyces polysporus and is located on a so-called ’glutamate nger’
[60]. Here and in Neurospora crassa and ermus thermophilus, the glutamate nger was shown to exist in
two dierent conformations that depend on target binding and facilitate cleavage activity [60]. Although
the inactive, ’plugged-out’ conformation has not been identied in other eukaryotic Agos [60], it is most
likely that the Ago4-specic insertion in this region aects positioning of the catalytic residues and/or
intramolecular rearrangements upon target binding.
1contributed by Prof. Dr. Rainer Merkl, University of Regensburg
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Figure 2.5: Comparison of the catalytic centers of Ago1, 2, and 4. (A) An overlay of the catalytic centers
of Ago2 (based on PDB 4OLA [58]) and Ago1 is shown. For Ago1 representation, a homology model
calculated on the basis of the published Ago2 structures [58, 59] was used. (B) e catalytic centers of
Ago2 and Ago4 are depicted in a dierent view. Here, the Ago4 homology model was built on basis of all
human Ago structures published by then, including structural information on Ago1 [58, 59, 61, 62].
2.1.4 The N-terminal domain aects cleavage activity of Ago1 and Ago4
Surprisingly, neither the activated Ago1 nor the activated Ago4 PIWI domain were able to cleave in the
full-length context of the individual proteins [Fig. 2.6 A (lane 4) and B (lane 3)]. Since two short sequence
elements in the N-terminal domain of Ago3 had been identied to inuence cleavage function (Fig. 2.2),
N-terminal changes were also applied to Ago1 and Ago4. In both proteins, substitution of the complete
N-terminal part with the Ago2 sequence showed that this region indeed aects cleavage activity [Figs.
2.6 A (lane 5) and B (lane 6), Fig. 2.6 C]. When only the rst of the two sequence elements identied in
Ago3 was changed in Ago1, this activity was maintained [Figs. 2.6 A (lane 6) and 2.6 C]. is indicates
that the second sequence element, mainly characterized by an Ago3-specic insertion, might also be an
Ago3-specic feature (Fig. 2.6 D).
To more precisely characterize cleavage-determining regions, a set of N-terminal mutants was analyzed
for Ago4 (Fig. 2.6 C). In contrast to Ago1, substitution of only the rst N-terminal sequence element did
not completely support cleavage function (Fig. 2.6 B, lane 7), but combination with the second sequence
element raised the activity to wild type levels (lane 8). Comparable endonucleolytic activity was de-
tected when the rst N-terminal region was shortened, nally encompassing an only ve amino acids
long ’FFEMD’ motif, which also had been shown to aect Ago3 cleavage function (lanes 8–11) [186]. Still,
reduction of the second sequence element or substitution of this element alone did not completely support
Ago4 endonucleolytic activity (lanes 12 and 13). Dierent from Ago3, Ago4 does not comprise an insertion
in this region, underscoring that not the Ago3-specic insertion alone obstructs cleavage activity (Fig. 2.6
D).
2.1.5 Ago cleavage mutants can unwind miRNA duplexes
e high sequence similarity of the four human Argonaute proteins supports the creation of functional
chimeras. Still, the implemented changes could aect Ago structure and function beyond endonucleolytic
activity. To exclude that loss of cleavage activity is caused by altered miRNA binding, the individual
mutants were tested for their miRNA binding ability. erefore, FLAG/HA-tagged Ago mutants were
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Figure 2.6: e N-terminal domain aects Ago1 and Ago4 cleavage activity. (A, B) Full length Ago1
(A) and Ago4 (B) mutants harboring cleavage-compatible PIWI domains were tested for cleavage activity
as described in Fig. 2.1. e activated PIWI domains of Ago2-1 PIWI DEDH cl2 (for Ago1, cf. Fig. 2.3)
and Ago2-4 DEDH ∆ cl2 (for Ago4, cf. Fig. 2.4) were used. (C) Schematic overview of Ago1 and Ago4
N-terminal mutants. Only the N-terminal parts of the chimeric proteins are shown. (D) Alignment of
the Ago1–Ago4 N-terminal domains. Substituted sequences are highlighted in red within the Ago2 se-
quence. e minimal substitutions necessary for Ago4 activation are shown in bold red. Numbering of
the substitution borders is based on the Ago2 sequence.
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Figure 2.7: All Ago cleavage mutants bind miR-19b. FLAG/HA-tagged Ago mutants were transfected
into HEK 293T cells and immunopuried by FLAG-IP. Co-purifying endogenous miR-19b and miR-19b*
were analyzed by Northern Bloing. Protein expression and IP eciency were controlled for by Western
Bloing. (A) miRNA binding of the Ago1 PIWI and full length mutants shown in Figs. 2.3 and 2.6. (B)
miRNA binding of the Ago3 domain and N-terminal mutants shown in Figs. 2.1 and 2.2. (C) miRNA
binding of the Ago4 PIWI and N-terminal mutants shown in Figs. 2.4 and 2.6.
expressed in HEK 293T cells and immunopuried. Associated RNA was isolated and analyzed by Northern
Bloing. As cleavage assays had been conducted with endogenously co-precipitating miR-19b, this miRNA
was also detected here. Importantly, all Ago mutants associate with miR-19b (Fig. 2.7). miR-19b* was not
detectable in any of the analyzed Ago IPs (Fig. 2.7 A and B), showing that the cleavage-inactive mutants
are also able to unwind the loaded RNA duplex.
2.1.6 Catalytically active human Agos rescue miR-451 processing in
Ago2-deficient mouse embryonic fibroblasts
One major function of human Ago2 is the processing of non-canonical miR-451. To test whether any
catalytically active Ago protein can fulll this function or whether a specic function of Ago2 is required,
catalytically activated Ago1, 3, and 4 (Fig. 2.8 A) were assayed for miR-451 processing in Ago2-decient
mouse embryonic broblasts (MEF Ago2 -/-). e cells were co-transfected with miR-451 and the dierent
Ago constructs. e mutants ’Ago1 N1-64’ (Fig. 2.6 A), ’Mut5’ (Fig. 2.2 C), and ’NT6’ (Fig. 2.6 B) were used
as catalytically active Ago1, 3, and 4. Total RNA was extracted and analyzed for miR-451 processing by
Northern Bloing (Fig. 2.8 B). ese experiments demonstrate that all cleavage-active Ago proteins can
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Figure 2.8: Catalytically active Ago proteins rescue miR-451 processing in Ago2-decient MEFs. (A)
Schematic overview of catalytically active and inactive Ago proteins. (B) MEF Ago2 -/- were co-transfected
with miR-451 and FLAG/HA-tagged Ago constructs, total RNA was isolated and assayed for miR-451
processing by Northern Bloing. RNA loading and quality was controlled by Ethidium Bromide (EtBr)
staining. Equal transfection eciency and protein expression was veried by immunopurication of the
FLAG-tagged Agos and Western Bloing from the same samples.
process pre-miR-451 (Fig. 2.8 B, lanes 3, 5, 7, and 9). e signal of mature miR-451 cannot be detected for
wild type Ago1, 3, and 4, which are catalytically inactive (lanes 2, 6, and 8). Mature miR-451 is also not
detectable in engineered cleavage-decient Ago2, which has an incomplete catalytic tetrad (lane 4). e
detection of weak bands at the height of mature miR-451 in non-slicer samples is most likely due to Ago
overexpression eects as it is not present without co-transfected protein (lane 1). ese results indicate
that slicer function alone is sucient for miR-451 processing.
Here, it was shown that catalytically inactive human Ago proteins can be turned into endonucleolytic
enzymes by sequence changes in their N domain (Ago3) or in their N and PIWI domains (Ago1 and Ago4).
is illustrates how paralogous proteins can adopt dierent functions on basis of their amino acid se-
quence. However, functionalization is also possible at the post-translational level. It is well known that
post-translational modications can inuence protein properties, thereby enabling one protein to fulll
dierent functions. In the context of characterizing human Ago proteins, the endogenous proteins were
analyzed for post-translational modications. As part of that, a new Ago purication strategy was es-
tablished and emerged as a powerful tool for the general characterization of Ago proteins. is novel
approach is characterized in the following section.
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2.2 Ago-APP: Ago Ainity Purification by Peptides
e binding of Ago to the human GW182 proteins TNRC6A, -B, and -C relies on interactions with trypto-
phans in the N-terminal half of the GW182 protein (cf. section 1.2). e exact region of Ago binding was
investigated by means of a peptide screen, which assayed overlapping peptides of the TNRC6B N-terminal
part for binding to human Ago2 [112]. is screen identied three major regions as interaction hot spots
(Fig. 2.9, [112]). Ago2 interacted strongly with a peptide containing one of these high anity binding
sites, TNRC6B599-683 (termed ’T6B’). is raised the question whether recombinant, GST-tagged T6B could
precipitate endogenous Ago proteins. e interaction of Ago and GW proteins is conserved within and
across species, implying that such a peptide purication strategy could be used as a multi-functional tool.
TNRC6B isoform 1
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Agotbinding
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Figure 2.9: Identication of a strongAgo-binding region in humanTNRC6B.A peptide screen identied
several regions in the TNRC6B N-terminal half that mediate Ago binding [112]. e amino acid sequence
of the best Ago-interacting peptide (TNRC6B599-683, ’T6B’) is shown and tryptophans are set bold.
2.2.1 A short TNRC6B peptide precipitates Ago proteins
In a rst approach, a conventional immunopurication of endogenous Ago2 was compared to a GST pull
down that used recombinant GST-tagged T6B with gluatathione sepharose beads. Indeed, the peptide-
based approach precipitates endogenous Ago2 as eciently as an Ago2-IP does (Fig. 2.10 A). Dierent
from an Ago2-IP, also a substantial amount of endogenous Ago1 is precipitated (Fig. 2.10 A).
To be able to apply standard tools that are based on α-FLAG purications, an N-terminal FLAG tag was
fused to GST-tagged T6B. FLAG-GST-T6B can be used with either FLAG or glutathione beads and precipi-
tates endogenous Ago2 as well as the GST-tagged peptide does (Fig. 2.10 B, compare lanes 8, 10, and 11). A
mutant version of the peptide, which lacks all tryptophan residues (’T6B mutant’) cannot precipitate Ago2
(lanes 7 and 9). Notably, the electrophoretic mobility of wild type and mutant T6B diers a lot, although
the proteins vary only slightly in their molecular weights (compare FLAG signal in lanes 7 and 8).
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Figure 2.10: GST-T6B precipitates human Ago1–4. (A) Comparison of Ago2-IP and Ago-APP. A mono-
clonal antibody against human Ago2 was coupled to Protein G Sepharose beads and a recombinant GST-
T6B peptide was coupled to glutathione beads. An unrelated antibody against Rmc and recombinant GST
were used for control-IP and -APP. e coupled beads were washed to remove excess antibody and pep-
tide, incubated with HeLa cell extract prepared in NET buer, and eluted with Laemmli buer. Ago1 and
Ago2 were detected by immunobloing. (B) Ago-APP and immunobloing using a FLAG-GST-T6B pep-
tide and a control peptide where all tryptophans were mutated to alanines (’T6B mutant’). FLAG- and
glutathione beads were used and GST-T6B was included as a control. (C) Ago-APP from HEK 293T cells
overexpressing FLAG/HA-tagged Ago1–4. Dierent amounts of the extracts were used to compensate
for dierential Ago expression. (D) Ago-APP from HEK 293T cells overexpressing the FLAG/HA-tagged
human PIWI proteins HIWI, HIWI2, and HILI. Ago2 was included as a positive control.
Next, the interaction of GST-T6B with all human Ago proteins was investigated. erefore, FLAG/HA-
tagged Ago and PIWI proteins were expressed in HEK 293T cells and precipitated by the peptide puri-
cation approach. Dierential expression of Ago1–4 was compensated for by using dierent amounts of
lysate. Indeed, human Ago1–4 can be precipitated by GST-T6B (Fig. 2.10 C). Notably, all four proteins
seem to be enriched to the same extend, suggesting that the T6B interaction is well-conserved and does
not discriminate between dierent Agos. In contrast to that, human PIWI proteins are not precipitated by
Ago-APP (Fig. 2.10 D).
e novel Ago purication strategy introduced here represents a favorable alternative to antibody-based
approaches. Hereaer, it is referred to as ’Ago Anity Purication by Peptides’ (’Ago-APP’).
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Figure 2.11: Ago-APP precipitates Argonaute proteins from dierent species (A) Protein extracts from
dierent sources were subjected to Ago-APP, separated by SDS-PAGE, and Coomassie-stained. e pro-
tein composition of potential Ago bands was analyzed by mass spectrometry. Lane 1 shows an Ago-APP
eluate that was obtained from elution with PreScission protease. e samples in lanes 2–5 were eluted
with Laemmli buer, which simultaneously eluted GST-T6B and aggregates of it (indicated by asterisks).
Drosophila: Drosophila melanogaster embryonic extract, Arabidopsis: Arabidopsis thaliana Landsberg
erecta PSB-D extract. (B) Summary of the mass-spectrometric results. Importantly, scores and sequence
coverage shown here rely on the MASCOT search parameters and do also take into account non-unique
peptides, i.e. peptides that cannot be assigned to one Ago paralogue. Hs, Homo sapiens; Mm, Musmusculus;
Dm, Drosophila melanogaster ; At, Arabidopsis thaliana.
2.2.2 Ago-APP precipitates Argonaute proteins from dierent species
Since overexpressed and endogenous Ago proteins from Ago-APPs could easily be detected by Western
Bloing, the peptide-based approach was tested for large-scale purications with subsequent Coomassie
staining. erefore, the amount of peptide-coupled beads was increased and total protein inputs were
scaled up to about 20 mg. Using HEK 293T cell extracts, a distinct Coomassie-stained band of about
100 kDa can be detected (Fig. 2.11 A, lanes 1 and 2). Two alternative elution methods were used in this
case—either the elution with PreScission protease, which cleaves o the peptide from its GST-tag and
provides high specicity (lane 1), or the elution with Laemmli buer, which is not specic (lane 2). e
dierences in specicity are obvious when comparing lanes 1 and 2.
Ago-APP puries endogenous Ago proteins in quantities that can be clearly visualized by Coomassie
staining. Consequently, the enriched Ago proteins can be analyzed by mass-spectrometric methods that
require large amounts of material, as is the case for the detection of phosphorylated residues. Further-
more, the strong enrichment of Ago proteins by Ago-APP facilitates the analysis of these proteins without
Western Bloing, i.e. without antibodies.
is was exploited when lysates of dierent origins were subjected to Ago-APP. For the murine neuronal
cell line N2A, the respective Coomassie band is as intense as the band observed in human samples (lane
3). Ago-APPs from Drosophila and Arabidopsis extracts result in fainter bands (lanes 4 and 5). e mass-
spectrometric analysis of these bands revealed that Ago-APP indeed puries Ago proteins from dierent
species, i.e. from human, murine, and Drosophila material and even from Arabidopsis extracts (Fig. 2.11
B). Importantly, band paerns that re-occur in these very dierent samples and cannot be detected in the
PreScission-eluted sample are due to peptide aggregates (Fig. 2.11, asterisks).
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Figure 2.12: Ago-APP facilitates miRNA isolation and depletion. (A) Ago2-IP and Ago-APP from HeLa
cell extracts were compared in terms of co-precipitating miRNAs. erefore, protein and RNA samples
from both purication strategies were analyzed by Western and Northern Bloing. Rmc-coupled Protein
G beads and GST-coupled glutathione beads were used as negative controls. IP and APP eciencies were
controlled for by immunobloing for Ago2. A probe against let-7a was used to detect co-precipitating miR-
NAs. (B) Schematic overview of an Ago- and miRNA depletion experiment. Peptide-coupled glutathione
beads were incubated with HeLa cell extracts and the supernatant of this reaction was transferred to a
second and a third aliquot of peptide-coupled beads. Protein and RNA samples of the lysates were taken
before and aer the incubation steps (IN, Sup). ’Ago-APP’ represents elutions of the anity-puried sam-
ples. (C) Western and Northern Blot analysis of the depletion experiment described in (B), immunobloing
and probes as in (A). A probe against U6 snRNA was used to control for equal RNA loading in input and
supernatant samples.
2.2.3 Analysis of co-precipitating small RNAs
To further characterize the T6B interaction with Ago proteins, miRNAs co-precipitating with Ago-APPs
were analyzed. A comparison with an Ago2-IP shows that Ago-APP puries loaded Ago proteins from
HeLa extracts (Fig. 2.12 A). It was shown in former Ago-APPs that the lysate cannot be depleted from Ago
by a single Ago-APP and that a certain amount of Ago remains in the supernatant (Fig. 2.10 A–D). To follow
up on this, a stepwise depletion experiment was conducted (Fig. 2.12 B, C). erefore, the supernatant of
a rst Ago-APP was incubated with fresh peptide-coupled glutathione beads and the supernatant of this
purication was again incubated with fresh peptide-coupled glutathione beads. A part of each of these
’input’/’supernatant’ and ’APP’ samples was analyzed by SDS-PAGE and Western Bloing. Ago2 as the
highest expressed human Ago protein was detected. e remaining part was used for RNA extraction and
Northern Bloing. Here, the exemplary miRNA let-7a was detected.
A stepwise decrease of Ago protein content can be observed both in APP and in input samples (Fig. 2.12
C), implying that a constant ratio of Ago proteins is engaged in the peptide interaction and that the
peptide-based purication relies on an equilibrium, most likely aected by the competition with full length
TNRC6B and by peptide binding itself. Aer the third purication step, Ago signals in the supernatant
are very low and the lysate is nearly depleted from Ago proteins. Interestingly, these observations are
reected in the miRNA analysis. As Ago2 levels decrease, let7a levels do also decrease (Fig. 2.12 C). is
correlation strongly suggests that neither free Ago proteins nor free miRNAs do exist.
2.2.4 Analysis of co-precipitating target RNAs
Since the peptide-based anity approach can be used to co-purify Ago-associated miRNAs, its potential
to enrich for co-precipitating target RNAs was investigated in the next step. erefore, Ago-APP was
again compared to a conventional Ago2-IP, which is known to enrich the let7 target HMGA2. One part
of the anity purications was used for Western Bloing, where Ago2 can be detected both in Ago2-IP
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Figure 2.13: Comparison of target RNA enriment in Ago2-IPs and Ago-APPs. (A) Immunodetection
of Ago2 in Ago2-IPs and Ago-APPs of HeLa cell extracts. (B) e enrichment of the let7 target RNA
HMGA2 was compared in Ago2-IPs and Ago-APPs. erefore, RNA was extracted from an input sample
and aer the anity purication, reverse-transcribed, and GAPDH and HMGA2 levels were determined
by quantitative real time PCR. Anity purications with an antibody against Rmc and with recombinant
GST were used as negative controls.
and in Ago-APP (Fig. 2.13 A). RNA was extracted from the remaining part of the purications, reverse-
transcribed, and analyzed for HMGA2 enrichment by quantitative real time PCR. erefore, HMGA2 levels
were related to unspecically copurifying GAPDH mRNA and compared to HMGA2 levels in an input
sample. A strong enrichment of HMGA2 mRNA can be detected in Ago2-IPs, whereas this mRNA is only
slightly enriched in Ago-APPs (Fig. 2.13 B). Importantly, a control-IP and a control-APP did not enrich
HMGA2. Hence, Ago-APP enriches miRNA targets only weakly, suggesting that full length TNRC6B is
necessary to eciently bind target RNAs.
2.2.5 Competition of T6B peptide and endogenous TNRC6B
If the weak target enrichment by Ago-APP is due to the absence of additional domains of the GW182
protein, this would suggest that the binding of T6B peptide to Ago replaces full length TNRC6B.
To investigate this possibility, a competition experiment of endogenous TNRC6B and recombinant GST-
T6B was performed. erefore, Ago2 was immunopuried from HEK 293T lysates containing overex-
pressed FLAG/HA-TNRC6B and from untreated lysates. First, an excess of GST-T6B was added to the IPs.
TNRC6B is co-immunopuried in Ago2-IPs without peptide, but the interaction is completely lost when
GST-T6B is added (Fig. 2.14 A, B).
Next, dierent amounts of GST-tagged peptide were incubated with the Ago2-IPs. e interaction of Ago2
and full length TNRC6B is lost when increasing amounts of GST-T6B are added (Fig. 2.14 C and D). e
slightly dierent competition eciencies in the FLAG/HA-TNRC6B-overexpressing and the endogenous
setup are most likely due to higher amounts of full length TNRC6B being present in overexpressing lysates.
Additionally, three times more total protein was used in these experiments. Importantly, TNRC6B does
still co-purify with Ago2 when a GST-tagged peptide lacking all tryptophans is used (Fig. 2.14 C and D,
’Ctrl’).
ese experiments show that GST-T6B competes for Ago binding with full length TNRC6B. Importantly,
addition of GST-T6B might be used as a strategy to specically elute GW182 proteins and associated
components from immunopuried samples.
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Figure 2.14: T6B peptide competes with full length TNRC6B. (A, B) Ago2-IPs were conducted in the
presence or absence of an excess of GST-tagged T6B in the lysate, using either HEK 293T extracts with
overexpressed FLAG/HA-tagged TNRC6B (A) or untransfected HEK 293T extracts (B). (C, D) Ago2-IPs
were conducted with dierent amounts of GST-T6B present in the lysate, using again HEK 293T extracts
with overexpressed FLAG/HA-tagged TNRC6B (C) or untransfected HEK 293T extracts (D). A GST-tagged
peptide lacking all ve tryptophans was included as negative control (’Ctrl’). A monoclonal antibody
against TNRC6B (clone 6G3) was used for TNRC6B detection in endogenous Co-IPs (B, D).
2.2.6 antification of Ago1–4 protein amounts in dierent tissues
Ago-APP allows to purify all human and murine Agos by using the same experimental tool. Until now,
most studies addressing cellular Ago1–4 levels relied on quantitative real time PCR data. antication
of protein levels was either based on IPs of the individual Agos by dierent monoclonal antibodies or
on shotgun proteomics [53, 102]. Since mammalian Agos show high sequence similarity, the assignment
of peptide masses can be ambiguous. Furthermore, slightly dierent peptides can show large dierences
in their mass-spectrometric properties (e.g. ionization and ight behavior), leading to potential technical
errors.
Here, the established peptide purication approach was used in combination with an MS-based selected
reaction monitoring (SRM) approach to reliably measure the relative quantities of human and murine Agos
from cell culture and tissue samples. During SRM, certain precursor ions are selected for fragmentation
and certain product ions are detected. is approach can be used for peptide quantication when a known
amount of a stable isotope-labeled, proteotypic peptide is spiked into the sample. e synthetic and the
sample peptide will be detected at similar retention times and can still be distinguished by their isotopic
mass dierence.
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Figure 2.15: Ago1–4 quantication from Ago-APPs and lysates of dierent human cell lines (A)
Endogenous Ago1–4 were puried from dierent human cell lines using Ago-APP. e eluates were
separated by SDS-PAGE, Coomassie-stained, and subjected to mass-spectrometric analysis. (B) Mass-
spectrometric measurements (selected reaction monitoring, SRM) of Ago-APPs and cell lysates that were
not subjected to Ago-APP. e laer were also separated by SDS-PAGE, Coomassie-stained, and the gel
region corresponding to the expected Ago size was cut and processed. Exactly known amounts of syn-
thetic, isotope-labeled peptides were spiked into the tryptic digests to allow for quantication of the four
Ago proteins (one isotope-labeled peptide per paralogue).
Several considerations were included during the selection of stable isotope-labeled peptides for Ago1–
4: First, the chosen peptide had to be unique for the individual Ago. Second, the peptide should be reliably
ionized and detected in MS analyses. And third, it would be advantageous if the same peptides could be
used for analysis of human and murine samples.
For quantitative measurements, Ago-APP was used to purify Ago1–4 from dierent human cell lines.
e eluates were separated by SDS-PAGE and stained with Coomassie Blue (Fig. 2.15 A). e Ago bands
were cut from the gel and prepared for in-gel tryptic digest. Dened amounts of the stable isotope-labeled
peptides were spiked into the tryptic digest, thereby facilitating quantication of the sample peptides from
the measured heavy:light ratios at a given retention time. To exclude any bias of Ago-APP towards one of
the four Ago proteins, a second set of samples was prepared by SDS-PAGE separation of lysate samples
without previous enrichment by Ago-APP.
e measured Ago amounts reect the published data well [53, 102, 112]. In all used cell lines, Ago2 is
the most abundant protein and contributes 50–80 % of the total Ago pool, followed by Ago1 (10–30 %) and
Ago3 (5–20 %). Ago4 is detected at very low quantities (1–2 %) (Fig. 2.15 B). e measured Ago ratios are
approximately the same in lysate samples. Again, Ago2 is most abundant, followed by Ago1 and Ago3. e
weakly expressed Ago4 cannot be detected directly from the lysate, indicating that previous enrichment
by Ago-APP is a necessary step, which increases reliability of the results.
Next, the relative Ago levels in dierent murine tissues were determined (Fig. 2.16 A and B). For these
measurements, an additional set of paralogue-specic synthetic peptides was used. Again, the measured
quantities reect the published data and the previous results well. Ago2 is most expressed in all analyzed
samples. e exact amounts of Ago1, Ago2, and Ago3 vary between the dierent tissues. ese variation
range from low Ago1 expression in muscle (ca. 5 %) to high Ago1 expression in brain (ca. 35 %). In contrast,
Ago3 expression varies only betwen 5 and 15 %. Ago4 is expressed in very low amounts in all tissues ex-
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Figure 2.16: antication of Ago1–4 in dierent mouse tissues (A) Endogenous Ago1–4 were puri-
ed from dierent murine tissues using Ago-APP. e eluates were separated by SDS-PAGE, Coomassie-
stained, and mass-spectrometrically analyzed. BAT, brown adipose tissue. (B) Ago1–4 quantication by
SRM measurements with stable isotope-labeled peptides (two synthetic peptides per paralogue). e rela-
tive amount of one Ago paralogue related to the total Ago pool is shown. Error bars represent the standard
deviation of identical samples that were quantied with two dierent paralogue-specic peptides. (C) e
relative amounts of Ago4 in dierent mouse tissues. Data were derived from the experiment shown in (A)
and (B).
cept of testis, where it contributes ca. 6 % of the total Ago pool (Fig. 2.16 C). is is in line with previously
reported quantitative real time PCR measurements and the Ago4 knockout phenotype observed in mouse
testes (Fig. 2.16 C) [100, 110].
Taken together, the advantages of Ago-APP, i.e. its pan-Ago properties and its cross-species applicability,
are of high value and open up numerous application possibilities. Moreover, Ago-APP is based on a high-
anity interaction and thereby facilitates the enrichment of large amounts of endogenous Ago proteins
for mass-spectrometric characterization. erefore, the use of Ago-APP represents a strong foundation
for the mass-spectrometric detection of phosphorylation sites on Ago proteins.
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2.3 Phosphorylation of endogenous Argonaute proteins
Ago proteins are key components of a machinery that post-transcriptionally regulates protein expression.
How are then Ago proteins regulated themselves?
Agos are post-translationally modied and the biological function of a few sites is known (section 1.3.2.1).
However, a substantial part of the studies that investigated Ago2 phosphorylation relied on overexpressed
Ago proteins. is has been necessary since the mass-spectrometric detection of phosphorylated peptides
is technically challenging and depends on large amounts of material. Here, dierent strategies were es-
tablished and optimized to purify large amounts of endogenous Ago proteins for the subsequent detection
of phosphorylation sites.
2.3.1 Purification of human Ago proteins
All extracts used for phosphorylation analyses contained the phosphatase inhibitors sodium uoride (a
serine and threonine phosphatase inhibitor) and sodium orthovanadate (a tyrosine phosphatase inhibitor).
First, Ago-APP, the newly established method described in 2.2, was used to purify Ago proteins. ere-
fore, the GST-tagged, Ago-binding TNRC6B peptide (GST-T6B) was coupled to glutathione sepharose,
excess peptide was removed, and the peptide-coupled anity matrix was incubated with cell extracts.
To shorten incubation times as much as possible, the samples were eluted with Laemmli sample buer
(Fig. 2.17 A). A second purication approach used covalent binding of a monoclonal antibody against hu-
man Ago2 to Co2+ iminodiacetate (IDA-Co) sepharose. HEK 293T cell extracts were rst precipitated by
ammonium sulfate, resuspended in PBS, and then incubated with the IDA-Co matrix. Aer elution, the
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Figure 2.17: Purication of endogenous Ago proteins. (A) Purication of human Ago1–4 by Ago-APP.
GST-T6B was coupled to glutathione sepharose and incubated with HEK 293T cell extracts. e sam-
ples were eluted with Laemmli buer, separated by SDS-PAGE, and stained with Coomassie Blue. (B)
Coomassie-stained SDS gel of an Ago2-IP. A monoclonal antibody against human Ago2 [187] was cova-
lently immobilized to Co2+ iminodiacetate (IDA) sepharose and incubated with HEK 293T lysate (Robert
He, Biochemistry I, University of Regensburg). (C) Co-immunopurication of human Ago1–4 with a
TNRC6A–C IP. A monoclonal antibody specic for human TNRC6A, -B, and -C was coupled to Protein
G Sepharose and incubated with HEK 293T lysates (Johannes Danner, Biochemistry I, University of Re-
gensburg).
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samples were separated by SDS-PAGE2 (Fig. 2.17 B). Finally, a third purication approach used the in-
teraction of endogenous TNRC6A, -B, and -C with Ago proteins. Here, monoclonal antibodies against
human TNRC6A–C were coupled to Protein G Sepharose and incubated with HEK 293T cell extracts in
a classical IP. Puried proteins were eluted with Laemmli sample buer and separated by SDS-PAGE3
(Fig. 2.17 B). All three purication strategies yield a distinct Ago band (Fig. 2.17 A–C). Importantly, Ago1,
Ago3, and Ago4 co-purify in the Ago-APP as well as in the TNRC6A–C Co-IP approach (Fig. 2.17 A and C).
2.3.2 Detection of endogenous phosphorylation sites of human Ago2
Samples obtained from the dierent anity purications were mass-spectrometrically analyzed for post-
translational modications. ereby, the focus was on the detection of phosphorylations. Fig. 2.18 sum-
marizes the results of dierent measurements and detailed data are listed in the Appendix (tables A.1–A.6).
For reasons of clarity, only potential phosphosites of Ago2 are shown. ese were retrieved from unique
peptides as well as from non-unique peptides, i.e. peptides that cannot be clearly assigned to one of the
Agos because of the high sequence similarity of human Ago proteins. Non-unique peptides that could
originate from Ago2 were included into the analysis because of the generally high expression levels of
human Ago2. Furthermore, only phosphorylated peptides with Mascot scores higher than 15 and expec-
tation values lower than 0.1 are shown. For comparison, Fig. 2.18 E represents published phosphorylation
sites of Ago2 as listed at PhosphoSitePlus® (www.phosphosite.org) (extended data in Tab. A.8).
e following part will point out several key aspects of the obtained phosphorylation data.
Confirmation of knownphosphorylation sites anddetection of newphosphorylation sites. Gen-
erally, potential phosphorylation sites of Ago2 can be detected in all samples and are distributed over the
whole protein. e potential phosphopeptides of the analyses conducted here overlap partially with al-
ready published phosphosites (compare Fig. 2.18 B–D to E). Importantly, one of the best-characterized
phosphorylated residues, S387, was detected in ve out of six analyses. Several phosphorylated residues
around amino acid 830 were also repeatedly detected. However, many residues have not been found to
be phosphorylated before and were reproducibly detected in the analyses presented here, e.g. residues
around amino acids 360, 540, or 560. ese ’new’ phosphorylation sites represent interesting candidates
for further characterization.
Dependence of phosphosite detection on the Ago purification method. Importantly, many of
the detected phosphorylation sites overlap between dierent analyses. ese sites occur in two mass-
spectrometric measurements of the same purication strategy (cf. Fig. 2.18 C) and in analyses of dierent
purication approaches. Based on the dierent purication approaches, one could speculate to enrich
dierent Ago pools by Ago2-IP and by TNRC6A–C Co-IP/Ago-APP. Indeed, S136, T337, and S776 are only
detected in TNRC6 Co-IPs, whereas T409 is only detected in Ago2-IPs.
Multiply phosphorylated peptides. In several cases, multiple phosphorylation sites were detected
within a short sequence region. ese ’phosphorylation clusters’ occur for example in the regions around
aa 360, aa 560, and, most prominent, around aa 830 (Fig. 2.18 B–D). e extended data show that two- to
fourfold-phosphorylated peptides of these cluster regions were detected (A.1–A.6).
2purication conducted by Robert He, Biochemistry I, University of Regensburg
3purication conducted by Johannes Danner, Biochemistry I, University of Regensburg
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Figure 2.18: Detection of potential phosphorylation sites in endogenous Ago2. (A) Length scheme of
Ago2 with one unit corresponding to one amino acid. (B–D) Overview of potential phosphorylation sites
that were detected by mass-spectrometric analyses of dierently puried Ago samples [(B) Co2+-IDA IP,
(C) TNRC6A–C Co-IP, (D) Ago-APP]. e gray bar represents Ago2 and potential phosphorylation sites
are indicated in red. Phosphopeptides with scores higher than 15 and expectation values lower that 0.1
were included. Only data of Ago2 are shown, but information of non-unique peptides were included. Ex-
tended data are shown in tables A.1–A.6. e mass spectrometers used for the individual measurements
are indicated on the right. (E) Published phosphorylation sites of Ago2 as listed at PhosphoSitePlus®, data
representation as in (B–D). Black bars and labeled residues represent phosphorylation sites that were con-
rmed by Ago-specic methods, red bars indicate phosphorylation sites that were detected by proteomic
screening methods only. Extended data are listed in Tab. A.8.
e data representation chosen here is simplied and exclusively based on the false discovery rate (FDR)
thresholds of database search engines. erefore, it needs to be combined with (a) information on the
individual peptides (data listed in tables A.1–A.6) and (b) manual validation of the fragment ion spectra.
As for the individual scores and expectation values of the detected phophopeptides, data quality varies a
lot between dierent analyses (A.1–A.6). e applied cuto values are not very restrictive, allowing for
comparison of low-condence phosphosites between dierent analyses. On the one hand, data quality
depends on the amount of protein that was available for mass-spectrometric analysis, i.e. input amounts
and eciency of the purication strategy. On the other hand, the used mass spectrometers have dierent
technical properties and analyses with the high mass accuracy MAXIS spectrometer yielded most reliable
data. Notably, the absence of a specic phosphosite in this representation (Fig. 2.18) can also be caused by
low sequence coverage of the respective region, a feature that is not represented here.
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2.3.3 Detection of endogenous phosphorylation sites of human Ago1–4
TNRC6A–C Co-IPs and Ago-APPs purify not only Ago2, but also Ago1, Ago3, and Ago4 (Fig. 2.17 A and
C). Potential phosphorylation sites of all human Ago proteins, the contribution of unique and non-unique
peptides, and sequence coverage were analyzed on the basis of the best obtained data set (Fig. 2.19 A–C,
Tab. A.7). Several key ndings of this analysis are summarized in the following subsection.
Unique and non-unique peptides. Most phosphorylated unique peptides were detected for Ago2.
e sequence coverage, which is based on several technical replicates and includes non-unique peptides,
is also highest here. Surprisingly, only a small part of all potential Ago2 phosphorylation sites is derived
from non-unique peptides (Fig. 2.19 B and C). Fewer phosphorylated unique peptides were detected for
Ago1, Ago3, and Ago4. e observed dierences in the number of phosphorylation sites are most likely
due to the dierent Ago expression levels and emphasize the dependence of MS-based phosphoanalytic
measurements on high protein quantities.
Paralogue-specific and -conserved phosphorylation sites. For both Ago1 and Ago3, paralogue-
specic phosphorylation sites were detected in the N-terminal region, the region with highest sequence
variability in human Ago proteins (Fig. 2.19 B). Furthermore, multiple phosphorylation sites in the re-
gion of aa 820–840 could be identied for Ago1, 3, and 4 and are completely based on unique peptides
(Fig. 2.19 B). One set of phosphorylations around aa 560 is detected as unique Ago2 peptide and as non-
unique Ago1/3/4 peptide, showing that at least two paralogues are modied at these sites (Fig. 2.19 B and
C). Finally, the phosphorylation sites corresponding to Y322, T337, and Y338 in Ago2 are derived from
peptides that are completely conserved in human Ago1–4 and can therefore not be assigned to one of the
paralogues.
Detection of novel phosphorylation sites in human Ago1, Ago3, and Ago4. A comparison of
Ago1, 3, and 4 phosphorylation data from this specic analysis with phosphorylation sites listed at Phospho-
SitePlus® shows that only lile overlap exists between the sites (Fig. 2.19 D, extended data in Tab. A.8).
e most prominent example of re-occurring phosphosites is again the cluster located around aa 830.
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Figure 2.19: Phosphorylation of human Ago1–4 (A) Length scheme for human Agos with one unit cor-
responding to one amino acid. (B) Representation of phosphorylation sites derived from unique phospho-
peptides of Ago1–4. ese were detected in a phosphosite analysis of Ago proteins from a TNRC6A–C
Co-IP (according to ’TNRC6A–C Co-IP II’ in Fig. 2.18). Data were retrieved from several technical repli-
cates and unied. e sequence coverage of the individual Ago proteins is shown on top of the phosphosite
representation and takes unique and non-unique peptides into account. (C) Representation of phospho-
rylation sites detected from non-unique peptides of the same mass-spectrometric analysis. Site positions
are based on the Ago1 sequence. Assignment to Ago1–4 is indicated at the le. (D) Ago1–4 phosphoryla-
tion sites as listed at PhosphoSitePlus®. Data representation as in Fig. 2.18 E, extended data are listed in
Tab. A.8.
2.3.4 Characterization of Ago2 phosphomutants
2.3.4.1 Location and conservation of potential Ago2 phosphorylation sites
From the obtained data, an initial set of several potential phosphorylation sites was chosen for further
analysis (Fig. 2.20 A). ese sites were primarily chosen because they are part of certain ’phosphorylation
clusters’, i.e. short sequence parts with a high number of detected phosphorylations. Whereas the clusters
Phos1 and Phos4 are located in linker regions of human Ago2, Phos2 is part of the Mid domain and Phos3
is located at the C-terminal end of the PIWI domain (Fig. 2.20 A).
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e phosphorylation clusters Phos1–4 are well conserved among the human Ago proteins, but also among
Ago proteins of dierent species (Fig. 2.20 B).
Structurally, these potential phosphorylation sites are either located at the surface of Ago2 (residues of
Phos1, Phos2, and Phos3) or in the small RNA binding channel (residues of Phos4) (Fig. 2.20 C). With that,
the investigated residues should be accessible for kinases, although this might be questionable in case of
the binding channel. Notably, some sites are located in probably very exible regions of the protein. is is
the case for Phos3 (Figs. 2.20 A and C)—this region is not resolved in the crystal structures of human Ago2
and assignment of the potential phosphorylation sites is based on template-free homology modeling.
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Figure 2.20: Location and conservation of potential Ago2 phosphorylation sites. (A) Schematic rep-
resentation of the Ago2 domain organization. e positions of identied phosphorylation sites are indi-
cated by red bars. e phosphorylation clusters Phos1–4 are highlighted by yellow boxes. (B) Alignment
of human Ago1–4 and Ago protein sequences from dierent species. e regions of the phosphoryla-
tion clusters are shown and potentially phosphorylated residues are highlighted. Amino acids are num-
bered according to the Ago2 sequence. Hs, Homo sapiens; Mm, Mus musculus; Rn, Raus norvegicus; Dm,
Drosophila melanogaster ; Ce, Caenorhabditis elegans. (C) Location of the identied sites within the protein.
An Ago2 homology model based on PDB 4OLA [58] was used to visualize residues that belong to exible
regions and are not resolved in the Ago2 structures. Two views of the protein are shown, domains are
labeled, and the positions of potential phosphorylation sites are shown in red.
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Figure 2.21: miRNA binding of non-phosphorylatable and phospho-mimiing Ago mutants.
FLAG/HA-tagged Ago mutants were overexpressed in HEK 293T cells, immunopuried, and co-
precipitating RNA was analyzed by Northern Bloing. miRNA association was analyzed of: (A) non-
phosphorylatable and phospho-mimicking Ago2 mutants of the identied phosphorylation clusters
Phos1–4, where all phosphorylatable residues were substituted by Ala or Glu (12 % urea PAGE). (B) the
phospho-mimicking triple, single, and double mutants of the cluster Phos4 (18 % urea PAGE). (C) an Asp-
containing Ago2 triple mutant and a Glu-containing Ago1 triple mutant of the cluster Phos4 (18 % urea
PAGE). A part of the immunopuried proteins was analyzed by Western bloing to ensure equal loading.
2.3.4.2 Analysis of miRNA binding and cleavage activity of a subset of Ago2 phosphomutants
One method to investigate the functional importance of phosphorylation sites is the analysis of non-
phosphorylatable and phospho-mimicking mutants. For that purpose, alanine and glutamate substitutions
are typically used.
An analysis of miRNA binding potential of the cluster phosphomutants showed that all non-phosphoryla-
table mutants can bind miR-19b, indicating that Ago2 is still functional (Fig. 2.21 A, lanes 3–6). e
phospho-mimicking mutants do also bind miR-19b (Fig. 2.21 A, lanes 9–12), although a slight shi can
be observed for Phos4 Glu.
e shi observed for Phos4 Glu was investigated by higher resolution gel separation and indeed, shorter
miRNA species are bound to this mutant (Fig. 2.21 B, lanes 1–3). To investigate if this is an additive eect of
the three mutated sites, single and double mutants were assayed as well. e miR-19b length distribution of
all single mutants resembles that of wild type Ago2 (Fig. 2.21 B, lanes 4–6), however, all double mutants are
associated with miR-19b of the lengths found in the triple mutant (Fig. 2.21 B, lanes 8–10). is indicates
that the observed miR-19b shortening is rather charge-dependent than site-specic. S220, T222, and Y225
are located in the small RNA binding channel (Fig. 2.20 C). Two models would explain the eect: either the
channel is opened up by structural rearrangements depending on the introduction of negative charges,
or the small RNA itself is repelled. Both scenarios would result in an increased accessibility of the small
RNA and, potentially, in 3’ trimming by a certain exonuclease or exonucleases in general.
To verify one of the proposed models, an aspartate triple mutant was tested (Fig. 2.21 C, lane 3). e
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Figure 2.22: Cleavage activity of non-
phosphorylatable and phospho-mimiing
Ago2 mutants. FLAG/HA-tagged Ago mu-
tants were overexpressed in HEK 293T cells,
immunopuried, and incubated with a radi-
olabeled substrate perfectly complementary
to the endogenously coprecipitating miR-
19b. RNA was extracted and resolved on a
sequencing gel. ’T1’ indicates a partial digest
of the radiolabeled substrate by RNase T1. A
part of the immunopuried protein was an-
alyzed by Western Bloing.
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shorter aspartate side chain would reduce miRNA shortening in case of a direct interaction with the small
RNA. In contrast, enhanced miR-19b shortening was observed (Fig. 2.21 C, lane 3), suggesting that protein-
protein interactions might be aected. In fact, a charge located deeper in a protein might induce a stronger
opening. Furthermore, a phospho-mimicking mutant of Ago1 Phos4 was tested. Surprisingly, this triple
mutant does not show any shortening of associated miR-19b (Fig. 2.21 C, lane 4).
Aer having conrmed miRNA binding, the chosen Ago2 mutants were tested for cleavage activity (Fig. 2.22).
All non-phosphorylatable mutants can cleave a radiolabeled target complementary to endogenous miR-
19b (Fig. 2.22, lanes 4–9). In contrast, two of the phospho-mimicking mutants, Phos2 Glu and Phos4 Glu,
show markedly reduced cleavage activity (Fig. 2.22, lanes 12–15). A Western blot analysis conrms equal
IP eciency of the individual proteins and miRNA binding of these mutants has been validated as well
(Fig. 2.21 A). Interestingly, a miRNA shortening eect was observed in one of the cleavage-compromised
mutants (Phos4 Glu). One can speculate that the introduced negative charges also aect the position of
the target RNA.
ese initial analyses of phosphomutants are based on few particular modication sites, which were iden-
tied by extensive phosphosite analysis of endogenous Ago2. ey provide a starting point and clearly,
more detailed characterization of these and other phosphomutants is necessary to integrate the obtained
information into Ago regulation and cellular signaling networks.
3. Discussion
Some Argonaute proteins are endonucleolytically active. eir enzymatic activity resides in the PIWI
domain and depends on the presence of four catalytic residues. However, the presence of this catalytic
tetrade is not sucient for slicer function, as exemplied by human Ago3 [3, 72, 73]. is work analyzed
the human non-slicers Ago1, Ago3, and Ago4. ereby, minimally changed, catalytically active Ago1,
Ago3, and Ago4 mutants were created and tested for catalytic activity. Several structural elements that
aect cleavage activity were identied. e rst part of this chapter is devoted to the newly identied
elements, their structural properties, and their possible functions during slicing.
Apart from the analysis of the slicer function of human Ago proteins, the present work addresses the
regulation of these proteins by phosphorylation. erefore, modication sites were supposed to be de-
tected by mass spectrometry. Since phosphorylations oen occur in substoichiometric amounts, their
mass-spectrometric analysis requires large amounts of protein. In the course of purication optimization,
a novel, peptide-based purication method was established. Ago-APP provides a powerful tool for the
species-independent analysis of Ago complexes in terms of associated RNAs and proteins. e second
part of this chapter discusses several key aspects of Ago-APP, whereas the third part summarizes and
discusses data obtained from dierent phosphorylation analyses.
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3.1 Turning catalytically inactive human Argonaute
proteins into active slicer enzymes
e analysis of human Ago1–4 in terms of their endonucleolytic activity identied several structural fea-
tures that inuence slicer function. First and most obvious, a complete catalytic tetrad consistent of DEDH
is required. ese residues are present in both Ago2 and Ago3, but the catalytic center is not complete
in Ago1 and Ago4 (Fig. 3.1, black/red). Second, two distinct regions in the N domain aect Ago cleavage.
While Ago1 only diers in the rst sequence element, Ago3 and Ago4 vary in both regions NTI and NTII
(Fig. 3.1, orange). Finally, two elements within the PIWI domain were identied. A region termed ’cluster
2’ is changed in both Ago1 and Ago4 (Fig. 3.1, blue), and an Ago4-specic insertion was found to addi-
tionally prevent cleavage activity (Fig. 3.1, yellow).
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Figure 3.1: Cleavage-dening elements of human Ago1–4 Overview of the four human Argonaute pro-
teins and the alterations, which turned them into catalytically active enzymes. For Ago1 and Ago2, the
X-ray structures (PDB IDs 4KXT and 4OLA)[58, 62] are shown. Ago3 and Ago4 are depicted by homology
models built on the published Ago1 and Ago2 structures. All changes needed to turn the individual Ago
proteins into slicer enzymes are highlighted. e bound guide RNA is shown in green.
3.1.1 The Ago N domain aects cleavage activity
e nding that the Ago3 N domain aects cleavage activity was unexpected since the catalytic activity
of Argonaute proteins was known to reside in the PIWI domain. However, deletion mutants of Drosophila
Ago1 and Ago2 lacking N and PAZ domains were reported to be beer slicers, suggesting that the N-PAZ
lobe aects slicer function [188].
e present study used manually created Ago chimeras to identify two regions in the Ago3 N domain
(aa 1–64 and 137–160), which inuence slicing. Schu¨rmann et al. identied these two regions as well
[186]. Instead of a manual approach, this study used a DNA shuing technique and could narrow down
the rst region to only ve amino acids, the so-called ’FFEMD motif’. Within this motif, the methionine
residue seems to aect slicing most [186]. e FFEMD motif is part of the rst region that was substituted
in the present work. Its importance was also addressed when the slicer function of human Ago4 was
analyzed. Indeed, substitution of only ve amino acids corresponding to the FFEMD motif in combination
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with substitution of a longer second region was sucient to activate the endonucleolytic activity of a
cleavage-compatible Ago4 PIWI domain.
An inuence of the N domain on slicer function was likewise observed in subsequent work [61]. Faehnle et
al. showed that the Ago2 N domain activates slicing in PIWI-adjusted Ago1, whereas the Ago1 N domain
negatively aects the endonucleolytic activity of Ago2 [61]. is study investigated also an Ago3 chimera
containing the Ago2 N domain. However, in this case Ago3 cleavage activity was much below Ago2 wild
type levels [61].
e molecular function of these N-terminal alterations are presently not clear. Structural modeling with
the available Ago structures revealed no denable inuence on the catalytic center. e N-terminal se-
quences identied in the present work are localized in loop regions that seem to be very exible, shown
by low structural resolution of these areas. Taking this into account, there may be a dynamic inuence
that ultimately aects the catalytic center and its positioning towards the guide and target RNAs.
Earlier studies showed that the N domain of human Ago2 aects unwinding of the RNA duplex in the
’pre-RISC’ complex, an Ago protein that is loaded with the RNA duplex resulting from Dicer cleavage [55].
Kwak et al. used conservation-driven alanine substitutions to identify several residues that aect removal
of the passenger strand. Since these residues are not localized to a certain region, the authors suggested
that movements and conformational changes of the whole N domain contribute to duplex unwinding [55].
In the present work, the association of Ago chimeras with miRNA and miRNA* strands was tested. All
Ago mutants associate with miR-19b, but not with miR-19b*, indicating functional unwinding (Fig. 2.7
A and B). is was expected since the used Ago mutants are based on amino acid exchanges with their
highly similar paralogues and all human Ago proteins are able to bind and unwind miRNA duplexes
[53]. e same results were obtained in the accompanying study that also investigated Ago3 cleavage
function [186]. Additionally, Schu¨rmann et al. assayed Ago mutants for unwinding of a perfectly comple-
mentary short hairpin RNA. ey observed that the passenger strand was continuously associated with
cleavage-decient Agos, conrming that Ago slicing function is important for endonucleolytic cleavage
of passenger strands and target RNAs [186].
Apart from its possible eects on catalytic center alignment and duplex unwinding, the Ago3 N domain
was suggested to obstruct the RNA binding channel [186]. Generally, eukaryotic Ago proteins adopt a
more open conformation with a wider RNA binding cle than prokaryotic Argonautes [60, 75]. Perfectly
complementary base pairing is necessary to initiate conformational changes, i.e. to release the miRNA 3’-
end from the PAZ domain and to position the catalytic center correctly [75, 80]. An obstruction of the RNA
binding channel may interfere with extensive base pairing and these rearrangements, ultimately impeding
on cleavage function. N-terminal changes aected also Ago1 and Ago4 slicer function (this work). Indeed,
a comparison of human Ago2 with the subsequently solved structure of human Ago1 revealed that two
co-called ’eukaryotic insertion elements’ correspond to regions that were substituted in the present work.
Noteworthy, these elements localize closer to each other in Ago1 and may therefore block the binding
channel [62].
However, it is presently not known to which extent the 3’-part of the RNA duplex is base-paired in human
Ago proteins and how it contacts the N domain. Remarkably, it was also hypothesized that the RNA-
binding cle of human Ago2 might be naturally blocked by the N domain and that this is necessary for a
’wedging’ function during duplex unwinding [55]. e role of the Ago N domain for slicer function will
most likely be unraveled by structural studies of human Ago2 with a perfectly paired target, which also
includes pairing with the 3’-part of the guide RNA.
Ago3 requires only N-terminal changes to gain cleavage activity. One might speculate that these changes
could also be induced extrinsically, for example by the interaction with binding partners or by post-
translational modications. However, such alterations have not been identied so far.
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3.1.2 Structural elements in the PIWI domain define cleavage function
is work identied two PIWI domain elements, which aect the cleavage activity of human Ago proteins.
A region termed ’cluster 2’ was identied in Ago1 and Ago4, whereas an additional insertion is specically
present in Ago4.
3.1.2.1 Cluster 2
Aer correction of the incomplete catalytic tetrade of Ago1, the protein (Ago1 DEDH) was still not cat-
alytically active (this work, [61]). For the same mutant, marginal slicing was observed in another study
[62], whereas intermediate activity was shown in a third one [186]. Paradoxically, cleavage activity of
wild type Ago1 or Ago1 DEDH has been reported before [52, 124].
e present work shows that Ago1 DEDH is not catalytically active. is lack of cleavage activity indicated
that additional PIWI domain elements may aect cleavage function. Here, cluster 2 (aa 670–680) was
identied. is is fully compatible with the ndings of Faehnle et al. who identied L674 and with those
of Nakanishi et al. who identied P670 and P675 to inuence slicer function [61, 62]. Notably, cluster 2
contributes also to slicer function of human Ago4 (this work).
Homology modeling and secondary structure analysis of human Ago1 on the basis of the Ago2 structures
that were available by then indicated that a short 310-helical element is present in cluster 2 of Ago2 and
connects a loop to an α-helix (Fig. 2.5 A). In Ago1, the 310-helix is missing and the region is characterized
by a longer loop and a shorter α-helix. ese dierences in secondary structure led to the hypothesis that
cluster 2 ultimately aects the position of a catalytic residue located in close proximity (Ago1 D667).
e crystal structures of human Ago1 revealed that this region, esp. the loop part, is indeed dierent from
Ago2 and protrudes further into the RNA binding channel [62]. Both Faehnle et al. and Nakanishi et al.
modeled an RNA duplex into the Ago1 structure [61, 62]. e rst group hypothesized the loop to interact
with the minor groove of the bound duplex and suggested that the loop, the glutamate nger, and the
target RNA undergo complex rearrangements to form the cleavage-competent catalytic center [61]. In
contrast, the model of the second group indicated that the loop interferes with correct placement of the
substrate opposite of the catalytic center [62].
Recent structural studies of human Ago2 added another line of evidence. Schirle et al. observed a magne-
sium ion in a catalytically inactive position of the catalytic center and suggested that perfect complemen-
tarity, esp. opposite of the cleavage site, is needed to reposition and activate the magnesium ion [74]. e
change of coordination partners during repositioning may also explain how certain structural elements
participate in formation of the active catalytic center [74].
3.1.2.2 The Ago4-specific insertion
Human Ago4 was catalytically activated, when, among other changes, an Ago4-specic insertion in the
PIWI domain was removed. Homology modeling showed that these residues form a helix-loop-helix el-
ement within the glutamate nger (Fig. 2.5 B). is does probably render the glutamate nger cleavage-
incompatible, either by a constitutive mis-positioning or by altering the exibility that might be required
for rearrangements that form the activated catalytic center.
Schu¨rmann et al. used their DNA shuing approach not only for the creation of Ago2–3 chimeras, but
also to create chimeras that contain sequences from all four human Ago proteins. None of the chimeras
containing Ago4 sequences in their N or PIWI domains was catalytically active [186]. is is surprising,
since this approach provides a vast number of chimeras. Notably, Schu¨rmann et al. were aware of the
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Ago4-specic insertion and deleted these residues. e sequence alterations were combined with changes
in the N-terminus, but not with changes in cluster 2. For that reason, a slicing version of Ago4 was not
identied in this study [186].
In the present work, the analysis of Ago4 conrms the structural elements that were found to aect Ago1
and Ago3 slicer activity. e protein, although evolutionary farthest related, complies clearly with the
same principles as the other human Ago proteins.
3.1.3 Human slicers provide new insights into Ago function
Taken together, the analysis of human Ago1–4 identied important structural features that account for the
endonucleolytic function of Ago proteins. On the one hand, an inuence of the N domain on slicer function
was revealed. On the other hand, specic structural elements in the PIWI domain were identied. ese
analyses provided information about Ago1, Ago3, and Ago4 that were not based on structural studies.
Remarkably, the solution of the Ago1 structure conrmed the structural divergence of cluster 2 [61, 62].
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3.2 Ago-APP: a novel purification strategy for Ago proteins
3.2.1 Evolutionary conservation of tryptophan-mediated interactions
Ago-APP is based on a tryptophan-containing peptide derived from the human GW182 protein TNRC6B.
is peptide and its interaction with Ago were characterized in detail in a recent study [112]. Notably, the
TNRC6B peptide is part of a region that has been linked to Ago binding before [129]. Mutation of a single
Trp residue located in this region (W623A) is sucient to abolish the interaction of TNRC6B with Ago,
indicating that this GW region is essential for Ago-binding [112, 129]. However, the Ago binding potential
of other GW regions (i.e. the conserved motif II and the ’Ago hook’ that is not present in all isoforms) has
been demonstrated as well [112, 154, 189, 190], altogether suggesting cooperative eects.
3.2.1.1 The specificity of Ago-APP
e presence of four Ago proteins and three GW182 proteins in humans suggests redundant functions
of both protein families. Indeed, members of the GW182 protein family associate with all Ago proteins
[128, 129, 190] and Ago paralogues bind all GW182 proteins [190]. Furthermore, the individual human
GW182 paralogues associate with a similar set of miRNA targets [107].
Binding of GW182 to Ago proteins is mediated by tryptophans that insert into two specic pockets. is
binding interface was rst identied in structural studies of human Ago2 [58] and is also present in human
Ago1 [62].
To understand GW182 binding to certain Argonaute proteins, residues that participate in formation of
the tryptophan binding pockets and GW182 binding were identied from the structure of human Ago2.
erefore, molecular distances and predicted residues of protein-protein interactions were determined
[191]1. Fig. 3.2 compares residues that most likely contribute to tryptophan binding in dierent Argonaute
proteins. Importantly, the identied residues are conserved in human and murine Ago1–4 (Fig. 3.2 A). In
contrast, the residues are not conserved in human PIWI proteins (Fig. 3.2 B). ese analyses consolidate
the binding specicities observed in Fig. 2.11 and are in line with previous reports [192].
A comparison of Drosophila Ago1 and Ago2 shows that the bioinformatically identied residues are well-
conserved in the miRNA-specic Ago1, but not in the siRNA-specic Ago2 (Fig. 3.2 C). Indeed, Drosophila
Ago2 is not puried by GST-T6B (Fig. 2.11) and does not bind GW182 proteins [134, 192, 193].
Importantly, the characterization of a GW peptide derived from another isoform of TNRC6B came to
similar conclusions concerning its specicity. e ’Ago hook’ was shown to bind to human Ago1 and
Ago2, but not to PIWI proteins in in vitro binding assays [154]. Furthermore, interaction with Drosophila
Ago1, but not with Ago2 was reported [154].
In addition, Ago-APP was successfully used with Arabidopsis extracts. However, the T6B peptide precip-
itates smaller amounts of Ago proteins from Drosophila and Arabidopsis lysates than from human and
murine extracts (Fig. 2.11). is could be due to expression dierences or the enrichment of only one or
two paralogues. Alternatively, if the anity of dierent Ago proteins might also be dened by the con-
servation of the tryptophan-binding pockets. Notably, less pocket-contributing residues are conserved
between human Ago2 and Drosophila Ago1 and conservation is even lower in Arabidopsis Argonautes
(data not shown). Hence, these bioinformatically identied residues might be used to roughly predict
specicity and eciency of Ago-APP in dierent experimental systems.
1contributed by Prof. Dr. Rainer Merkl and Lukas Kater, both University of Regensburg
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Figure 3.2: Bioinformatic analysis of Ago2 residues that form tryptophan binding poets e struc-
ture of human Ago2 (PDB ID 4EI1, [58]) was used to identify residues that are in close proximity of the
tryptophan binding pockets. Additional residues with high interaction probability (specied by conser-
vation, solvent accessibility, hydrophobicity, and local environment of the residues) were identied by
PresCont [191]. Conservation of the identied residues was compared by sequence alignments of human
and mouse Ago proteins (A), human PIWI proteins (B), and Drosophila Ago proteins (C)
3.2.1.2 Tryptophan-mediated protein interactions: a common theme
As already introduced, many interactions of GW182 proteins depend on tryptophans (cf. subsection 1.2.2).
Similar tryptophan-mediated interactions have been observed in dierent systems and for other binding
partners. One example is Tas3, which is part of the RITS complex in S. pombe and mediates transcriptional
gene silencing of centromeric regions [154, 194].
Moreover, multiple examples of tryptophan-dependent protein association have been recognized in plants.
Since Arabidopsis Ago4 and Ago9 were identied in Ago-APPs, the following part gives an overview of
plant Agos, small RNA-guided gene silencing, and Trp-mediated interactions in plants.
Ago proteins and small RNA-guided gene silencing in plants. Ten Ago proteins are encoded in
the Arabidopsis genome [48, 195]. e proteins associate with small RNAs of dierent length and are
implicated in diverse processes such as conventional miRNA silencing of endogenous genes (Ago1), virus
defense (Ago2), or production of trans-acting siRNAs (tasiRNAs, Ago2 and Ago7) [48]. Furthermore, RNA-
directed DNA methylation (RdDM) events are very common in plants and a group of Agos—namely Ago4,
Ago6, and Ago9—is dedicated to mediate transcriptional repression by cytosine methylation [196–198].
e RdDM Agos interact with the plant-specic polymerase V, which is involved in siRNA production,
e.g. from repeats, transposons, or transgenes [199–201]. ey are specically loaded with 24 nt long siR-
NAs produced by DCL3 (Dicer-like 3) [198].
Plant miRNAs usually target RNAs with near-perfect complementarity and therefore target cleavage plays
an important role [202]. In contrast to most other Ago-expressing species, there is no GW182 homologue
in plants [134]. Still, Ago4 and Ago9 were enriched by Ago-APP.
Enrichment of RdDM Agos by Ago-APP. Purication of RdDM Agos by the GW peptide can be at-
tributed to their interaction with the C-terminal domain (CTD) of the polymerase V subunit NRPE1. is
protein is characterized by GW motifs similar to those of GW182 proteins [155]. When the GW-containing
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region of NRPE1 is substituted by an unrelated sequence, de novo DNA methylation is abolished, demon-
strating that it fullls an essential function during RdDM. Notably, the GW-containing, plant-specic CTD
precipitates human Ago2 in GST pull down assays [155]. Even a chimeric CTD containing the GW-rich re-
gion of human TNRC6A is able to purify Arabidopsis Ago4 in these assays [155]. Moreover, this chimeric
protein can partially reconstitute DNA methylation in NRPE1-decient plants [155].
Homology modeling indicated that both tryptophan binding pockets are conserved in plants [203], si-
multaneously raising the question of why only Agos of the Ago4/6/9 subfamily can be precipitated by
Ago-APP.
GWmotifs as conserved Ago binding platforms Several additional plant GW proteins were identi-
ed, all of which interact with at least one Arabidopsis Ago protein and function at dierent steps of DNA
methylation pathways [204–208]. Interestingly, viral suppressor proteins exploit GW-based interactions
to interfere with antiviral silencing [209, 210].
Taken together, Ago-APP can be used to specically enrich Agos of the RdDM pathway and to characterize
associated components.
3.2.2 Ago-APP co-depletes Ago proteins and miRNAs
e T6B peptide used for Ago-APP resembles the function of a pan-Ago antibody and puries miRNA-
loaded Agos. is feature was used to estimate the Ago:miRNA ratios in the cell (Fig. 2.12). In a stepwise
depletion experiment it was shown that at least in HeLa extracts and at least for let-7a, miRNAs are
depleted from the lysate to the same extent as Ago proteins. ese ndings suggest that Ago proteins and
miRNAs exist as complexes and that their levels are interdependent.
In contrast, Janas et al. used depletion of Ago1–4 by a pan-Ago antibody and showed that associated
miRNAs are not depleted to the same extent. Complemented by protein and miRNA quantication data,
the authors of this study concluded that a pool of non-Ago-bound miRNAs exists in the cell [124]. Two
other reports point into a similar direction, showing that free miRNAs exist and that dierent miRNAs
associate with Ago proteins to dierent extents [125, 126]. However, with the powerful tool of Ago-APP
being available, these ndings are hard to explain.
e stepwise depletion of Ago proteins from HeLa extract shows that Ago and miRNAs are co-depleted,
suggesting that both components exist as complexes. Furthermore, the near-complete depletion of Ago
proteins from the lysate indicates that Ago-APP discriminates not between dierent Ago pools, but targets
all Ago proteins of a cell. is is in line with mass-spectrometric characterization of Dicer-dependent
(miRNA-loaded) and Dicer-independent (unloaded) Ago complexes, both of which were found to associate
with TNRC6B [211].
3.2.3 Eicient target binding requires full length GW182 proteins
Interestingly, co-immunopurications of endogenous Ago2 and TNRC6B in the presence of GST-T6B
showed that the peptide is able to compete with endogenous TNRC6B (Fig. 2.14). Moreover, Ago-APP
does not enrich for miRNA target RNAs to the same extent as a classical Ago2-IP does (Fig. 2.13). ese
observations suggest that the short Ago-binding peptide is not sucient to stabilize target RNA binding
to Ago. Most likely, additional GW182 domains are necessary to stabilize the interaction. is has not
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been realized so far and only few observations hint at a mechanistic interplay of additional GW182 do-
mains and target binding. For example, PAM2-mediated PABP binding is hypothesized to facilitate RISC
binding to target RNAs [144]. However, although GW182 proteins feature an RRM, a direct interaction of
GW182 proteins with target RNAs has not been reported so far. e RRM is most likely used for protein
interactions [212]
Experimentally, strategies like conventional UV crosslinking or UV crosslinking of 4-thiouridine could
be used to obtain stable Ago complexes. is would allow to combine Ago-APP with target identication
approaches such as PAR-CLIP (Photoactivatable-Ribonucleoside-Enhanced Crosslinking and Immunopre-
cipitation).
3.2.4 Establishment of an Ago1–4 quantification method
In this work, Ago-APP and subsequent SRM analyses with stable isotope-labeled peptides were used to
reliably determine Ago1–4 protein levels. Generally, the measured protein levels mirror the data obtained
from previous analyses, although these analyses were performed with lower accuracy [53, 102, 112]. How-
ever, not much aention has been payed to Ago4 protein levels so far, mostly because Ago4 is expressed
below detection limits in many tissues. Nevertheless, analysis of Ago4 transcript levels by quantitative real
time PCR had already indicated thatAgo4 expression is increased in testes [110]. More precisely, this study
indicated that Ago4 transcript levels equal those of Ago2 or are even twice as high [110]. In the present
work it was shown that Ago4 protein contributes ca. 5 % of the total Ago pool. is is substantially less
than expected from Ago4 transcript quantication. Most likely, the huge dierence between Ago4 tran-
script and protein levels can be accounted for by suboptimal codon usage in Ago4 [111]. It seems that
the resulting, small Ago4 pool is responsible for the phenotype observed in Ago4 knockout mice [100].
Several questions arise from this nding: Why are transcription and translation of Ago4 so ineciently
coupled? Does the suboptimal codon usage resemble a mechanism to additionally downregulate Ago4
protein expression in all other tissues than testes? And nally, how does Ago4 functionally dier from
the other human Ago paralogues?
Apart from these conceptual questions, the combination of Ago-APP and SRM measurements established
in this work represents the rst and reliable absolute quantication that can be used both for human and
murine samples. Numerous application possibilities are conceivable, ranging from Ago1–4 quantication
under dierent conditions to modication quantication of a single Ago paralogue. With that, the estab-
lished method might assist in clarifying potential specic functions of individual Ago proteins and is a
valuable tool for the site-specic analysis of post-translational modications.
3.2.5 Ago-APP: A novel tool for the characterization of endogenous Ago
complexes
e novel Ago purication strategy established in the present work represents a valuable tool for the char-
acterization of Ago proteins and associated (small) RNAs. Main advantages in contrast to conventional
immunopurications lie in its high yields, its pan-Ago properties, and its cross-species applicability. In-
deed, the data presented here suggest that Ago-APP can be used to enrich Ago proteins from all species
that rely on GW182-dependent gene silencing.
e universal applicability of Ago-APP opens numerous possibilities: First, endogenous Ago proteins
themselves can be characterized. is is also shown in this work where Ago-APP, among other puri-
cation strategies, was applied to detect endogenous phosphorylation sites of human Ago2 (cf. section
2.3). Second, Ago-APP can be used to characterize Ago-associated miRNAs. is can be of interest for
52 3. DISCUSSION
miRNA validation in species where antibodies are not available or for general miRNA proling of all Ago-
associated miRNAs in a specic lysate. ird, Ago-APP can be optimized and adapted for target RNA
proling. is has been prepared by providing a FLAG-GST-tagged peptide which can be easily used with
established PAR-CLIP protocols. Importantly, target RNA proles aer Ago-APP will represent the spec-
trum of all miRNA-regulated transcripts and it is not yet known if this diers from Ago2-regulated target
RNAs. Finally, peptide-derived tools can be used to monitor miRNA-mediated silencing of certain tar-
get RNAs. erefore, the T6B peptide is available in an eukaryotic expression vector with an N-terminal
FLAG/HA-tag and a C-terminal GFP-tag that was introduced to protect the unstructured, short peptide
from degradation. Indeed, a luciferase reporter carrying the HMGA2 3’-UTR is de-repressed upon co-
transfection with this peptide version (data not shown2).
Furthermore, Ago-APP can be used as a tool to enrich for RdDM Argonautes and to dissect the RdDM
pathway in plants. However, Ago yields are relatively low when using plant lysates and one might consider
the establishment of an analogical technique that utilizes the GW motifs present in the CTD of Arabidopsis
polymerase V subunit NRPE1. is is further consolidated by the observation that chimeric CTDs carrying
the human TNRC6A GW motifs are able to interact with plant Ago4, but interaction is relatively weak
compared to human Ago proteins [155].
Apart from these application possibilities of Ago-APP, several limitations of the method should be con-
sidered. First, Ago-APP relies on hydrophobic tryptophan interactions and depends therefore on lysis
buers with low amounts of detergent. Second, metabolically highly active lysates (e.g. liver lysate) are
prone to degrade the peptide, making it necessary to add high amounts of protease inhibitors. ird,
GST-T6B can be easily used with glutathione beads, but these are sensitive to the actual redox state. is
can be a problem when using lysates or lysate additives with a high oxidation potential, e.g. the tyrosine
phosphatase inhibitor Na3VO4. Importantly, the use of FLAG-GST-T6B with an α-FLAG-coupled anity
matrix circumvents this problem.
2contributed by Daniel Schraivogel, University of Regensburg
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3.3 Endogenous phosphorylation sites of human Ago
proteins
For phosphorylation analysis, dierent purication approaches, including Ago-APP, were used to yield
large amounts of endogenous Ago2 and Ago1–4, respectively. e data obtained from mass-spectrometric
analysis represent a detailed resource of endogenous phosphorylation sites present in endogenous Ago2
under standard cell culture conditions.
3.3.1 Endogenous phosphorylation sites of human Ago2
To summarize, the application of dierent purication methods cross-conrms several modication sites,
but yields also sites that might be specically enriched by one method. is is especially interesting since
TNRC6-Co-IPs and Ago-APPs were applied. Both methods are based on the interaction of Ago and GW182
proteins and might therefore preclude and/or require certain modications.
Moreover, previously characterized sites such as pS387 [177, 179] were reliably detected and conrm the
experimental approaches used here. Still, a signicant part of the detected phosphorylations has not
been reported before. erefore, these sites represent interesting candidates for further analysis. For
comparison, publicly available data collected at PhosphoSitePlus® (www.phosphosite.org) were used. It
is obvious that not all previously known sites were reproduced. is is probably due to the use of dierent
experimental systems and conditions, but one should also note that many sites listed at PhosphoSitePlus®
were exclusively obtained from large-scale proteomic screens, implying relatively low reliability compared
to modications that were analyzed site-specically.
Interestingly, phosphorylation clusters and multiply phosphorylated peptides were detected for human
Ago2. Biological and technical aspects of this nding are discussed in the following section.
3.3.1.1 Phosphorylation clusters and multiply phosphorylated peptides of human Ago2
Conservation. e most prominent phosphorylation cluster detected in the present analyses encom-
passes ve potential phosphorylation sites between aa 824 and 834 (cluster ’Phos3’). Importantly, four
phosphorylatable residues are conserved in Ago1–4 (Fig. 2.20 B) and unique phosphorylated peptides of
this region have been detected in Ago1, Ago3, and Ago4 (Fig. 2.19 B). ese residues are conserved across
species (Fig. 2.20 B). Indeed, multiply phosphorylated residues corresponding to this cluster have been de-
tected in the C. elegans Ago protein ALG-1 (data not shown3). Considering the generally low conservation
of phosphorylation sites [213], this is remarkable and strongly indicates functional importance.
Biological function. A systematic analysis of phosphosite distribution in eukaryotes showed that phos-
phorylated serine and threonine residues tend to occur in clusters [214]. Several clustered phosphoryla-
tions with dierent biological functions have been described [215].
For example, phosphorylated repeats in the C-terminal domain of RNA polymerase II provide multiple
highly specic binding platforms. eir phosphorylation paern changes during transcription, adapting
the repertoire of associated transcription factors to the transcription phase [216]. Clustered phosphoryla-
tions were also observed in the Saccharomyces cerevisiae protein Sic1, a cyclin-dependent kinase inhibitor.
3collaboration with Martin Simard, Laval University, ebec City (Canada);
data contributed by Astrid Bruckmann, University of Regensburg
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Here, the number of phosphorylated residues is more important than their position. When six out of nine
potential sites are phosphorylated, an ubiquitin ligase binds to Sic1 and targets it for degradation, ensuring
onset of the cell cycle [217, 218].
At the molecular basis, clustered phosphorylations result in local charge accumulation and oen inuence
protein interactions. is involves binding to other proteins, especially if these rely on ionic interactions
or if phosphates are recognized in (or excluded from) binding pockets [215]. Moreover, multiple phospho-
rylations can disrupt membrane association or DNA binding [219, 220]. However, the analysis of miRNA
binding and cleavage function of phospho-mimicking and non-phosphorylatable Ago2 Phos3 cluster mu-
tants showed that small RNA and target RNA binding are not aected by the negative charge introduced
here (Figs. 2.21 and 2.22).
Mechanistically, phosphorylation clusters represent biological switches whose mode of action, rheostat
or binary switch, is determined by cooperative eects between individual phosphorylatable sites [215]. In
addition, clustered phosphorylations were suggested to ensure evolutionary robustness [214].
Asking for kinases. e detection of multiply phosphorylated peptides intensies the questions of im-
plicated kinases. Are all residues phosphorylated by one kinase with low specicity? Or is there crosstalk
between phosphorylation sites, i.e. does modication of a certain position alter kinase specicity of a
neighboring position?
Few kinases, so-called ’priming-dependent’ kinases, depend indeed on phosphorylated sites. Many sub-
strates of GSK3 (glycogen synthase kinase 3) require a priming phosphorylation at a serine four amino
acids downstream of the actual modication site [221]. e same is true for CK1 (caseine kinase 1),
which depends on serine phosphorylations three positions upstream of the modication [222]. ese
phosphorylation-dependent kinases were observed to cooperate at one substrate [223].
In context of the phosphorylation sites detected here, such a mechanism would turn S828 into a key
residue, with S824 being potentially phosphorylated by GSK3 and S831 and S834 being modied by CK1.
Phosphosite analysis of a S828A non-phosphorylatable mutant will provide information about implication
of these priming-dependent kinases.
Technical challenges. e mass-spectrometric analysis of phosphopeptides is generally dicult, which
is for example due to their poor ionization eciency and their specic fragmentation behavior. Since some
of these diculties depend on negative charges, the analysis of multiply phosphorylated peptides is even
more problematic [224]. Furthermore, the assignment of phosphorylations to a certain amino acid can
be ambiguous when several phosphorylatable residues are present and when fragment ion spectra do not
provide sucient sequence information [225]. Additionally to that, rearrangements of phosphorylations
in the gas phase have been observed, implementing another positional uncertainty factor [226].
Apart from mass-spectrometric issues, cluster phosphorylations can be dicult to handle during site-
specic analysis. First, the design of appropriate phosphomutants would require information on site-
specicity or minimum number of phosphorylated residues. Since these information are usually not avail-
able, a large number of combinatorial mutants has to be used to narrow down possible phenotypic eects.
Second, phosphosite-specic antibodies generally represent a valuable tool. However, these antibodies
are highly specic and will in many cases not recognize a phosphorylated residue when the neighboring
residue is phosphorylated as well.
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3.3.2 Phosphorylation sites of human Ago1, Ago3, and Ago4
e present work focused mainly on endogenous phosphorylation sites of human Ago2. However, since
TNRC6-Co-IPs and Ago-APPs purify the other human Ago proteins as well, an exemplary analysis of
paralogue-specic modication sites was included (Fig. 2.19). Phosphorylation of human Ago1, Ago3,
and Ago4 has not been characterized by site-specic methods before and available data are exclusively
based on high-throughput screens. is is most likely the reason for the large variations between the sites
detected here and previously known sites listed at PhosphoSitePlus®.
Two observations are apparent from the paralogue-specic phosphorylations identied here: First, unique
phosphorylated peptides of the cluster ranging from aa 824–834 can be detected in all human Ago par-
alogues and show conservation of this region in terms of post-translational modications. Second, para-
logue-specic phosphorylations are present in the N-terminal regions of Ago1 and Ago3. is is of par-
ticular interest since N-terminal regions of both Ago1 and Ago3 were shown to negatively aect endonu-
cleolytic function (cf. 3.1.1). One could speculate that post-translational modications in these regions
contribute to fulll structural requirements necessary for slicing.
3.3.3 Characterization of selected Ago2 phosphomutants
One subset of potentially phosphorylated residues was chosen for further characterization by means of
non-phosphorylatable and phospho-mimicking mutants. In the present work, the assessment of miRNA
binding and cleavage activity is shown. ese functional assays revealed two main ndings.
First, a phospho-mimicking Ago2 mutant of cluster 220–225 (Phos4) binds shorter miRNAs than wild
type Ago2 or a non-phosphorylatable mutant (Fig. 2.21 B, lanes 1–3). Site-specic analysis showed that
the phenotype depends rather on the number of negative charges than on the exact modication site.
Surprisingly, this is an Ago2-specic eect. It does closely resemble the observation that wild type Ago2
associates preferentially with shorter miRNA species [95, 121]. It is not known if the observed eect is
due to loading of shorter miRNAs or shortening of the miRNA aer incorporation into the Ago2 mutant.
Additionally, it is not known to which extent 3’-shortening of a miRNA would aect the identity of bound
targets.
Second, a phospho-mimicking cluster mutant of aa 555–561 (Phos2) has reduced endonucleolytic function
(Fig. 2.22, lane 13). Interestingly, the recently published structure of human Ago2 with bound target RNA
shows that S561 engages in specic interactions with the target RNA [74], making this and neighboring
residues candidates for modication-regulated target binding.
However, it has oen been observed that mutant side chains mimick phosphorylations only partially.
As an example, phosphorylation of Ago2 Y393 decreases Dicer binding, whereas a phospho-mimicking
mutant does not [181]. erefore, mutant approaches should be complemented by dierent methods.
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3.3.4 Phosphorylation of Ago proteins—an outlook
Here, several potential phosphorylation sites of human Ago2 were identied mass-spectrometrically. Im-
portantly, the representation of phosphosites in Fig. 2.18 is based on search engine thresholds and does
not include manual validation of fragment ion spectra.
In a rst step of functional characterization, a subset of mutants was characterized in terms of miRNA
binding and cleavage activity. ese functional assays should be complemented by assays which provide
information about association with binding partners (e.g. Dicer, GW182 proteins, other RISC components),
cellular localization, and stability of the phosphomutants.
Apart from the clustered phosphorylations shown here, many dierent sites have been detected and are
currently characterized, among them are also paralogue-specic phosphorylations.
To understand Ago function, it is essential to analyze regulatory networks that aect its post-translational
modication. For all detected sites, involved kinases and phosphatases and their implication into signal-
ing pathways remain completely open questions. Since many kinases depend on vaguely-dened con-
sensus sequences, sequence-based predictions are oen ambiguous. Future approaches for the identi-
cation of modifying enzymes will for example include kinase inhibitor screens combined with the mass-
spectrometric detection of Ago phosphorylation paerns. Moreover, in vitro phosphorylation experiments
could be used for kinase identication and the evolutionary conservation of Phos3 in C. elegans may pro-
vide further information.
antication of phosphorylated residues is another step towards understanding the functional impor-
tance of these modications. A well suitable method for protein quantication has been established as
part of this thesis. It is based on protein enrichment by Ago-APP and subsequent mass-spectrometric
protein quantication by means of stable isotope-labeled peptides. In the present work, this approach has
been used to quantify Ago paralogues. It is straightforward to adapt it to the quantication of phosphory-
lated peptides under dierent conditions. Since Ago-APP is based on conserved interactions, this would
facilitate phosphorylation quantication in many species and enable phosphorylation analyses beyond
cell culture systems.
4. Material and Methods
4.1 Material
4.1.1 Consumables and chemicals
All frequently used chemicals were purchased from Sigma-Aldrich (St. Louis, USA), Merck (Whitehouse
Station, USA), Roth (Karlsruhe, Germany), AppliChem GmbH (Darmstadt, Germany) and ermo Fisher
Scientic (Waltham, USA) at the highest degree of purity.
Radiochemicals were obtained from Hartmann Analytic GmbH (Braunschweig, Germany), whereas sta-
ble isotope-labeled peptides were purchased from JPT Peptide Technologies GmbH (Berlin, Germany).
Oligonucleotides were synthesized by Metabion GmbH (Planegg, Germany). Cell culture reagents were
purchased from Sigma-Aldrich (St. Louis, USA). Enzymes, nucleotides, and molecular weight markers
were obtained from ermo Fisher Scientic (Waltham, USA), unless stated otherwise.
e composition of individual buers is specied with the respective method they were used for (sections
4.2–4.4).
4.1.2 Bacterial strains and cell lines
Bacterial strains and cell lines are listed in Tables 4.1 and 4.2.
Table 4.1: Bacterial strains
strain genotype
XL1-blue F– recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac F’[proAB
lacI qZ∆M15 Tn10 (TetR)]
Bl21 (DE3) F– dcm ompT lon hsdSB(rB- mB-) gal λ(DE3)
Rosea F– dcm ompT lon hsdSB(rB- mB-) gal λ(DE3) pRARE (CamR)
Bl21 (DE3) Gold pRARE F– dcm ompT Hte lon hsdSB(rB- mB-) gal EndAI λ(DE3) pRARE (CamR)
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Table 4.2: Cell lines
cell line specication
HEK 293T human embryonic kidney cells
HeLa human cervical cancer cells
LNT-229 human glioma cells
MCF-7 human breast cancer cells
MEF Ago2 -/- mouse embryonic broblasts
N2A mouse neuroblastoma cells
4.1.3 Vectors, oligonucleotides, and cloned constructs
4.1.3.1 Vectors
Used vectors are listed in Tab. 4.3.
Table 4.3: Vectors
vector name resistance tag application
VP5 (modied pIRES neo) Amp, Neo N-terminal FLAG + HA eukaryotic expression vector;
used for all Ago mutants
pUC18 Amp none cloning
pGEX-6P-1 Amp N-terminal GST prokaryotic expression vector;
used for T6B peptide expression
pEC-K-3C-GST Kana N-terminal 6× His + GST prokaryotic expression vector;
used for T6B peptide expression
4.1.3.2 Constructs
FLAG/HA-tagged GFP and FLAG/HA-tagged human Ago1–4 were described before [72]. A codon-optimized
Ago4 construct was used to generate Ago4 chimeras [111]. However, Ago4 PIWI domain sequences
were amplied from the wild type Ago4 sequence. e mutants Ago3–2 PIWI, Ago2–3 PIWI, MutA,
MutB, MutC, MutD, Ago2–1 PIWI, and a pUC18 construct encoding a perfectly complementary target
RNA for miR-19b were provided by Simone Harlander (Biochemistry I, University of Regensburg). e
target RNA sequence for miR-19b was described before [72]. Ago1 DEDH was provided by Dr. Sabine
Ru¨del (Biochemistry I, University of Regensburg). FLAG/HA-tagged HIWI, HIWI2, and HILI were pro-
vided by Prof. Dr. Gunter Meister. e pSUPER plasmid encoding miR-451 shRNA was described before
[95]. 6×His-GST-tagged TNRC6B(599-683) (termed ’GST-T6B’) and 6×His-GST-tagged TNRC6B(599-683)
W623A W634A W653A W666A W680A (termed ’GST-T6B mutant’) are based on the vector pEC-K-3C-
GST and were described before [112].
Tab. 4.5 includes an overview on all constructs used in the present work. It lists the oligonucleotides that
were used to generate them and indicates the respective cloning strategies.
All Ago constructs were cloned into the eukaryotic expression vector VP5 via NotI/EcoRI.
TNRC6B constructs for the recombinant expression of FLAG-GST-tagged peptides were subcloned into
pGEX-6P-1. erefore, TNRC6B 599-683 (wild type and mutant) was amplied from the pEC-K-3C-GST
constructs [112] and inserted into pGEX-6P-1 via BamHI/NotI. Two overlapping DNA fragments were
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Table 4.4: Oligonucleotides for Northern Bloing, quantitative real time PCR, sequencing, and in vitro
transcription scale up PCRs
oligonucleotide orientation ID sequence (5´→ 3´)
Probes for Northern Blotting
miR-19b fwd TCAGTTTTGCATGGATTTGCACA
miR-19b* 1/2 fwd ATGCAAACCTGCAAAACT
miR-451 fwd AACTCAGTAATGGTAACG
let-7a fwd AACTATACAACCTACTACCTCA
U6 snRNA fwd GAATTTGCGTGTCATCCTTGCGCAGGGGCCATGCTAA
Oligonucleotides for quantitative real time PCR
GAPDH fwd ATGGGTGTGAACCATGAGAA
GAPDH rev GTGCTAAGCAGTTGGTGGTG
HMGA2 fwd CGATTTCTACCTCAGCAGCA
HMGA2 rev GGAAAGACCATGGCAATACA
Sequencing primers
T7 fwd TAATACGACTCACTATAGGG
VP5 seq rev rev JH s4 CCCAACAGCTGGCCCTCGCAGA
M13 fwd TGTAAAACGACGGCCAGT
Ago1 int 1 fwd SH s16 GCCAGTGATTGAGTTCATGTGTG
Ago1 int 2 fwd SH s17 AGGTGCTCAAGAACTTCACAGA
Ago2 int 1 fwd SH s14 GGCACAGCCAGTAATCGAGT
Ago2 int 2 fwd SH s15 CGGAAGTCCATCTGAAGTCCT
GST N-Term rev JH s5 CATGTTGTGCTTGTCAGCTATATAACG
Oligonucleotides for amplication of in vitro transcription templates
T7 rev SH1 TAATACGACTCACTATAGAACAATTGCTTTTACAG
SP6 fwd SH2 ATTTAGGTGACACTATAGGCATAAAGAATTGAAGA
amplied from the obtained constructs (’FLAG I’ and ’FLAG II’ in Tab. 4.5). In this step, the FLAG sequence
and a short linker region containing a BglII restriction site were inserted 5’ of the GST tag. e overlapping
parts were annealed, lled up by Phusion DNA Polymerase, and inserted into the vector backbone via
EcoRV/NotI.
4.1.3.3 Oligonucleotides
Oligonucleotides were diluted in water to a working concentration of 10 µM (primers) or 20 µM (probes)
and stored at−20 °C. Tab. 4.5 lists oligonucleotides used for cloning and Tab. 4.4 lists all other nucleotides.
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4.1.4 Antibodies
Table 4.6: Primary and secondary antibodies. Hs, Homo sapiens; Mm, Mus musculus. WB, Western Blot-
ting; IP, immunoprecipitation.
antibody origin application dilution supplier
antibodies against endogenous proteins
α–Hs Ago1, clone 1C9 rat WB 1:5
α–Hs Ago2, clone 11A9 [187] rat WB, IP 1:5
α–Mm Ago2, clone 6F4 rat WB 1:5 Dr. E. Kremmer,
α–Hs TNRC6B, clone 6G3 rat WB 1:5 Helmholtz Zentrum
α–Hs TNRC6A–C, clone 7A9 rat IP 1:5 Mu¨nchen
α–Hs TNRC6A–C, clone 11C12 rat IP 1:5
α–Rmc rat IP 1:5
antibodies against tags
α–HA, clone 16B12 mouse WB 1:1000 Covance Research Products
α–FLAG M2 rabbit WB 1:1000 Sigma-Aldrich
secondary antibodies
α rat IRDye® 800CW goat WB 1:10,000 LI-COR Biosciences
α mouse IRDye® 800CW goat WB 1:15,000 LI-COR Biosciences
α rabbit IRDye® 800CW goat WB 1:5,000 LI-COR Biosciences
4.1.5 Exactly quantifiable heavy peptides for SRM measurements
Peptides were obtained as SpikeTides™ TQL peptides contain an exactly quantiable tag that is
cleaved o during tryptic digest and 15N/13C-labeled C-terminal lysine (+8 kDa) or arginine (+10
kDa). Amino acid sequences of the proteotypic peptides used in selected reaction monitoring
experiments are listed in Tab. 4.7.
Table 4.7: Stable isotope-labeled peptides used for relative quantication of Ago paralogues by selected
reaction monitoring
paralogue paralogue-specic paralogue-specic
(human/mouse) peptide I peptide II
Ago1 VLPAPILQYGGR NIYTVTALPIGNER
Ago2 DYQPGITFIVVQK VLQPPSILYGGR
Ago3 SANYETDPFVQEFQFK SFFSAPEGYDHPLGGGR
Ago4 QVAWPELIAIR EFGIVVHNEMTELTGR
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4.1.6 Technical equipment
device supplier
Mass-spectrometric equipment
maXis plus UHR-QTOF Bruker (Billerica, USA)
CaptiveSpray nanoBooster Source Bruker (Billerica, USA)
QTRAP®4500 AB SCIEX (Framingham, USA)
NanoSprayIII Ion source AB SCIEX (Framingham, USA)
Chromatography system for both mass spectrometers:
UltiMate 3000 RSLCnano System ermo Fisher Scientic (Waltham, USA)
with Acclaim® PepMap100 C18 Nano-Trap col-
umn (300 µm i.d.× 5 mm)
and Acclaim® PepMap C18 column
(75 µm i.d.×150 mm)
Other equipment
FastPrep®24
(with Lysing Matrix D)
MP Biomedicals (Santa Ana, USA)
Odyssey Infrared Imaging System LI-COR Biosciences (Lincoln, USA)
Personal Molecular ImagerTM (Phosphoimager) Bio-Rad Laboratories, Inc. (Hercules, USA)
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4.2 Generation of DNA constructs
4.2.1 Polymerase Chain Reaction (PCR), restriction digests, and ligation
e composition of a standard PCR reaction and standard cycling conditions are listed below.
Site-directed mutagenesis, PCR conditions for the generation of chimeric products, and 3-way
blunt end cloning procedures are listed in the subsections 4.2.2–4.2.4.
PCR Mix, 50µl
5–50 ng DNA template
1× HF Buer
0.2 mM dNTPs
0.5µM reverse primer
0.5µM forward primer
2 U Phusion
DNA Polymerase
Cycling Conditions
Initial denaturation 98 °C 30 s
Denaturation 98 °C 10 s
Annealing 55–72 °C 30 s
Elongation 72 °C 1 min/kbp
Terminal elongation 72 °C 10 min
25–30 cycles
PCR products were separated on 0.7–2 % agarose gels, cut, and gel-extracted using the NucleoSpin®
Gel and PCR Clean-up kit (MACHEREY-NAGEL GmbH). For preparative restrictions, the whole
PCR reaction (alternatively 2µg of plasmid DNA) was incubated with the appropriate FastDi-
gest restriction enzymes (ermo Fisher Scientic) at 37 °C. To prevent religation of vectors, 2µl
FastAP ermosensitive Alkaline Phosphatase (ermo Fisher Scientic) were added to the re-
striction mix aer 4–6 h and incubated at 37 °C for 30 min. e restricted DNA was either directly
puried by the NucleoSpin®Extract II kit or separated on 0.7–2 % agarose gels rst.
For ligations, 50 ng of the cut and dephosphorylated vector were incubated with the 4 × molar
excess of the restricted insert, 0.1 U/µl T4 DNA Ligase (ermo Fisher Scientic), appropriate
buer and eventually PEG 4000. Ligations were incubated at 22 °C for 1 h before proceeding to
transformation.
4.2.2 Site-directed mutagenesis (’ikChange’)
Single amino acid changes were inserted by site-directed mutagenesis. erefore, the whole plas-
mid was amplied with mutagenic primers and template DNA was removed by DpnI digestion.
e composition of the PCR reaction and cycling conditions for ikChanges are listed below.
PCR Mix, 50µl
50 ng template DNA
1× HF Buer
0.2 mM dNTPs
0.2µM reverse primer
0.2µM forward primer
1 U Phusion
DNA Polymerase
Cycling Conditions
Initial denaturation 98 °C 30 s
Denaturation 98 °C 10 s
Annealing 55 °C 30 s
Elongation 72 °C 1 min/kbp
Terminal elongation 72 °C 10 min
18 cycles
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4.2.3 Generation of Chimeras
For chimeric constructs, a terminal cloning primer and an internal chimeric primer were used.
e shorter part of the construct was amplied rst using the rst template. erefore, a standard
PCR as described in 4.2.1 was performed. e resulting product resembles an elongated primer.
It was used together with the other terminal cloning primer to amplify the second part of the
construct from the second template. e composition of the second amplication reaction and
cycling conditions are listed below.
PCR Mix, 50µl
250 ng template DNA
1× HF Buer
0.2 mM dNTPs
300 ng PCR I
0.25µM primer
1 U Phusion
DNA Polymerase
Cycling Conditions
Initial denaturation 98 °C 30 s
Denaturation 98 °C 10 s
Annealing 55 °C 45 s
Elongation 72 °C 1 min/kbp
Terminal elongation 72 °C 10 min
25–30 cycles
4.2.4 Mutagenesis by 3-way blunt end ligation
e substitution of longer sequence stretches was achieved by generation of two PCR fragments
that each carried part of the intended alterations at the ’central end’ and a restriction site at
the ’external end’. Aer restriction, the fragments were phosphorylated with T4 Polynucleotide
Kinase (ermo Fisher Scientic) and ligated into a cut and dephosphorylated vector in a three
way blunt end ligation. Here, PEG 4000 was added to increase ligation eciency.
4.2.5 Transformation of E. coli
For transformations, chemically competent E. coli (XL1-blue for propagation pf plasmid DNA;
Bl21 (DE3) and Rosea for prokaryotic protein expression) were thawed on ice. Approximately
0.5µg of DNA were used for re-transformations, whereas 10µl ligation mixture were used for
cloned constructs. For site-directed mutagenesis, up to the whole volume of the DpnI-digested
and puried PCR product was used. e cells were incubated on ice for at least 10 min and sub-
jected to a 30 s heatshock at 42 °C thereaer. Aer 5 min incubation on ice, 1 ml of LB medium
was added, and the cells were incubated at 37 °C for at least 20 min while shaking. For re-
transformations, 30µl were plated on LB plates containing the appropriate antibiotic. For cloning,
the whole volume was plated. LB plates were incubated overnight at 37 °C.
4.2.6 Extraction of plasmid DNA from E. coli
For overnight cultures, 5 ml of LB containing the appropriate antibiotic were inoculated with a
single colony. To screen large numbers of clones by analytical digests, a fast DNA extraction
method was applied [227]. Briey, 2 ml of the overnight culture were pelleted and resuspended
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in 40 µl EasyPrep Buer. e samples were incubated at 99 °C for 1 min, followed by an in-
cubation on ice for 1 min, and clearance by centrifugation at 15,000 g for 15 min. 5–10 µl of the
supernatants were used for analytical digests with 0.1µl of the appropriate FastDigest restriction
enzyme(s) (ermo Fisher Scientic).
For all other applications than analytical digests, plasmid DNA was extracted by means of the
NucleoBond® Plasmid and Xtra Midi kits (MACHEREY-NAGEL GmbH) according to the manu-
facturer’s protocols.
LB medium 10 g/l NaCl, 5 g/l yeast extract, 10 g/l tryptone (pH 7.2–7.5)
EasyPrep Buer 10 mM Tris/HCl (pH 8), 1 mM EDTA, 15 % saccharose, 2 mg/ml lysozyme,
0.2 mg/ml RNase A, 0.1 mg/ml BSA
4.2.7 Sequencing
Plasmid DNA was sequenced by GATC Biotech AG (Ko¨ln, Germany), SEQLAB Sequence Lab-
oratories Go¨ingen GmbH (Go¨ingen, Germany), or Macrogen (Amsterdam, e Netherlands).
Sequencing primers are listed in Tab. 4.4.
4.3 Protein-based methods
4.3.1 Expression and purification of recombinant protein
Wild type and mutant T6B expression constructs were transformed into chemically competent
E. coli Bl21 (DE3) GOLD pRARE (constructs present in pEC-K-3C , i.e. GST-T6B wild type and
mutant) or Bl21 (constructs present in pGEX-6P-1, i.e. FLAG-GST-T6B wild type and mutant).
Typically, recombinant GST-tagged proteins was puried from 2–3 l of bacterial culture. Cells
were grown at 37 °C to an optical density (OD) of 0.4, incubated at 18 °C until an OD of 0.6 was
reached, and protein expression was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside
(IPTG). e cultures were harvested aer incubation overnight at 18 °C.
For initial experiments, protein was batch-puried. erefore, the bacteria pellet of 1 l culture
was resuspended in 25 ml Resuspension Buer. Aer cell lysis by sonication, the lysate was
incubated rotating at 4 °C for 30 min and claried by centrifugation at 10,000 g. Per 1 l culture
volume, 1 ml of Glutathione Sepharose 4 Fast Flow (50 % slurry, GE Healthcare) was washed
with cold PBS two times. e lysate were added to the washed matrix and incubated rotating at
4 °C for 2 h to let GST fusion proteins bind to the glutathione matrix. ereaer, the matrix was
washed with cold PBS three times and loaded onto a gravity ow column (Bio-Rad Laboratories).
Elution was carried out in ve steps by addition of each 0.5 ml elution buer. e owthrough
was collected in microcentrifuge tubes. A shortened Bradford test was used to optically assess
the protein content of the eluted fractions. erefore, 1–5 µl of an elution fraction were diluted
in 1 ml 1 × Bradford Reagent (Bio-Rad Laboratories). Protein-containing fractions were unied
and dialyzed against 1 l PBS two times for each 1–2 h. Dialyzed protein was aliquoted and stored
at −80 °C.
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Resuspension Buer PBS supplemented with 1× Complete Protease Inhibitor Cocktail (Roche Di-
agnostics GmbH (Mannheim, Germany), 0.1 mg/ml lysozyme, 10 U/ml ben-
zonase, 0.1 mM DTT, 0.5 % Triton X-100, 10 mM MgCl2
Glutathione Elution Buer 20 mM glutathione, 50 mM Tris/HCl pH 8, 120 mM NaCl
For large scale purications1, the bacterial cell pellet was resuspended in GST-A. Aer sonica-
tion, the lysate was claried by centrifugation at 40,000 g for 40 min and loaded onto a 15 ml
Glutathione Sepharose column (GE Healthcare). e column was washed with 10 colume vol-
umes (cv) of GST-A before the GST-tagged protein was eluted in 4 cv of GST-B. e fractions
containing the GST fusion protein were concentrated and further puried by a desalting chro-
matography column (HiPrep 26/10 Desalting, GE Healthcare) equilibrated in PBS supplemented
with 5% gylcerol. Desalted fractions were adjusted to ca. 2 mg/ml and stored at −80 °C.
GST-A PBS supplemented with 1 mM AEBSF, 1 mM DTT, 1 mg/ml lysozyme
GST-B PBS supplemented with 20 mM Tris pH 8.0, 10 mM glutathione
4.3.2 Cell culture
Human and murine cells were cultured under standard conditions (37 °C, 5 % CO2) using Dul-
becco’s modied Eagle’s medium (DMEM, Sigma-Aldrich) supplemented with 10% FBS (Sigma-
Aldrich) and Penicillin/Streptomycin (Sigma-Aldrich). An overview of the cell lines used in the
present work is given in Tab. 4.2.
4.3.2.1 Transfection by calcium phosphate
HEK 293T cells were transfected using calcium phosphate, ideally at a conuency of 30 %. Per
15 cm plate, 5–15µg DNA and 123µl of 2 M CaCl2 were lled up to 1 ml with water in a reaction
tube. In a second reaction tube, 1 ml of 2×HEPES-buered saline was prepared. e DNA-
containing solution was addded to the HEPES-buered saline while shaking. e mixture was
incubated at room temperature for 10 min and thereaer carefully added to the cells. e cells
were harvested aer 24–48 h.
2×HEPES-buered saline 274 mM NaCl, 1.5 mM Na2HPO4, 54.6 mM HEPES (pH 7.1)
4.3.2.2 Transfection by Lipofectamine LTX and PLUS Reagent
MEF Ago2-/- cells were transfected by Lipofectamine® LTX and PLUS™ Reagent (ermo Fisher
Scientic) according to the manufacturer’s protocol. Briey, the cells were seeded to 6-well plates
in antibiotics-free medium one day before transfection. Transfection was ideally performed
at about 80 % conuency. erefore, 2.5µg of DNA (for co-transfections 2 × 5µg DNA) were
diluted in 100µl Opti-MEM® I Reduced Serum Media (ermo Fisher Scientic) and 2.5µl of
PLUS™ Reagent were added. Aer 5 min incubation, 17.5µl Lipofectamine® LTX were added
1conducted by Leonhard Jakob, Biochemistry I, University of Regensburg
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and the mixture was incubated at room temperature for 20 min. e cell culture medium was
changed before the Lipofectamine mixture was applied to the cells. e cells were harvested 2 d
aer transfection.
4.3.3 Lysate preparation
4.3.3.1 Lysate preparation from cell culture samples
Cells were usually grown on 10 cm or 15 cm cell culture dishes. For cell harvest, the medium was
removed thoroughly and 1–1.5 ml of cold PBS were added. A rubber policemen was used to scrape
the cells o the plate. e cells were transferred to 2 ml reaction tubes and pelleted for 10 min at
200 g. e supernatant was removed and the pellet was either lysed directly or frozen in liquid
nitrogen and stored at−80 °C. For cell lysis, the pellet was resuspended in 0.5–1.3 ml lysis buer
and incubated on ice for 20 min. Generally, NET buer was applied for immunopurications
and Ago-APPs, whereas RIPA buer was used for FLAG-IPs and subsequent RISC cleavage as-
says. V Buer does not contain ingredients that interfere with the tyrosine phosphatase inhibitor
Na3VO4 and was therefore used for Ago-APPs that were intended for mass-spectrometric anal-
ysis of phosphorylation sites. Aer lysis, the cell debris was removed by centrifugation (20 min
at 15,000 g).
NET buer 50 mM Tris/HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5 % NP-40, 10 % Glyc-
erol, 1 mM NaF, 0.5 mM DTT, 1 mM AEBSF
RIPA buer 50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 0.1 % SDS, 1 % sodium deoxycholate,
1 % NP-40, 1 mM NaF, 0.5 mM DTT, 1 mM AEBSF
V Buer 10 mM HEPES pH 7.5, 150 mM NaCl, 10 % glycerol, 0.5 % NP-40, 1 mM NaF,
5 mM Na3VO4, 1 mM AEBSF
4.3.3.2 Lysate preparation from tissues
Mouse tissue lysates were prepared in 800µl NET buer. e tissue was mechanically disrupted
using FastPrep®-24 with lysing matrix D (45 s at 6.5 m/s,). ereaer, the ceramic beads were
spinned down for 1 min at 13,000 g. e supernatant was transferred to a new reaction tube and
the ceramic beads were washed with NET buer once. e supernatants of the disruption and
washing steps were united and spinned down at 15,000 g for 30 min.
Arabidopsis cell extract was obtained from suspension cultured PSB-D cells as described before
[228]. Drosophila embryonic extracts were obtained as described before [229].
4.3.4 Immunoprecipitation (IP)
For IPs of endogenous proteins, monoclonal antibodies were coupled to Protein G Sepharose (GE
Healthcare). Depending on the amount of input material, 30–100µl beads were washed with
cold PBS twice and coupled with 0.5–1.5 ml hybridoma supernatant for at least 3 h, preferably
overnight. e coupled beads were washed with PBS twice to remove excess antibody.
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For IPs of FLAG/HA-tagged proteins that were overexpressed in HEK 293T cells, anti-FLAG M2
agarose (Sigma-Aldrich) was used. Prior to use, the matrix was washed with cold PBS twice.
Eventually, the total protein concentration of the lysate was determined by a short Bradford
test. Input samples of the lysates were taken, mixed with Laemmli sample buer, and stored at
−20 °C. For immunoprecipitation, the lysate was incubated with the antibody-coupled beads for
at least 3 h while rotating at 4 °C. Aer incubation, supernatant samples were taken and mixed
with Laemmli sample buer. e anity matrix was sedimented by centrifugation for 1 min at
1,000 g and the supernatant was removed. e beads were washed with the lysis buer four times.
During the rst washing step, the samples were transferred to new reaction tubes to minimize
contamination by unspecic protein binding to the tube material. Aer a nal washing step with
PBS, the supernatant was removed quantitatively and the beads were eluted by addition of 2 ×
Laemmli sample buer.
5×SDS sample buer 300 mM Tris/HCl pH 6.8, 10 % SDS, 62.5 % glycerol, 0.05 % bromophenol blue,
10 % β-mercaptoethanol
4.3.5 Ago-APP (Ago Ainity Purification by Peptides)
Ago-APP is based on a GST pulldown approach. In the rst step, recombinant 6×His-GST-
TNRC6B(599-683) (termed ’GST-T6B’) or 6×His-GST-TNRC6B(599-683) W623A W634A W653A
W666A W680A (termed ’GST-T6B mutant’) was coupled to Glutathione Sepharose (GE Health-
care). erefore, the beads were washed with cold PBS twice. At least 100µg of the peptide were
added to 50µl beads (50 % slurry) in 0.5–1 ml PBS. e coupling reaction was incubated for a min-
imum of 1 h while rotating at 4 °C. Aer coupling, the beads were washed with cold PBS three
times to remove excess peptide. Next, the lysate, optimally prepared in NET buer, was added
to the peptide-coupled beads. e samples were incubated for 3 h while rotating at 4 °C. ere-
aer, the anity matrix was transferred to a new reaction tube and washed with NET buer four
times. Aer a nal washing step with PBS or PreScission Cleavage Buer, the supernatant was
removed quantitatively and the beads were eluted using one of the following strategies:
• elution by SDS sample buer: most stringent
2 × SDS sample buer was added to the beads and incubated at 95 °C.
• elution by Glutathione Elution Buer: selective
At least the packed bead volume of Glutathione Elution Buer was added and incubated
with the beads at room temperature for 30 min.
• elution by PreScission Cleavage: selective
PreScission Cleavage Buer and 0.1µg/µl PreScission Protease were added to the beads
and incubated overnight at 4 °C.
Glutathione Elution Buer 20 mM GSH, 50 mM Tris/HCl pH 8, 120 mM NaCl
PreScission Cleavage Buer 50 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM DTT
4.3. PROTEIN-BASED METHODS 71
4.3.6 SDS-PAGE, Western Blot, and Coomassie staining
Depending on the molecular weight of the protein of interest, 6 % or 10 % SDS polyacrylamide
gels were used. For input and supernatant samples, 25–100µg of total protein was loaded. For
eluates of anity-puried samples, loading volumes depended on the type of subsequent anal-
ysis. e maximum possible volume (approximately 100µl aer widening the wells) was loaded
for subsequent mass-spectrometric identication of phosphorylation sites. SDS polyacrylamide
gels were run at 140 V until the dye front had passed the stacking gel. ereaer, voltage was
increased to 220 V and the gel was run until the dye front had completely passed it.
stacking gel 125 mM Tris/HCl pH 6.8, 0.1 % SDS, 0.15 % TEMED, 5 % Acrylamide/Bis so-
lution (37.5:1), 0.05 % APS
Separating gel 380 mM Tris/HCl PH 8.8, 0.1 % SDS, 0.1 % TEMED, 6–10 % Acrylamide/Bis
solution (37.5:1), 0.05 % APS
SDS Running Buer 25 mM Tris, 192 mM glycine, 1 % SDS
For Western Bloing, three equally-sized Whatman papers and a Hybond ECL membrane (GE
Healthcare) were soaked in Towbin Bloing Buer and placed on the positive electrode. e SDS
gel was equilibrated in Bloing Buer and transferred to the layers. ree additional Whatman
papers of the same size were soaked in Towbin Bloing Buer, placed on top of the gel, and air
was removed. Western Blots were performed at 10 V with a bloing time of 1–3 h (approximately
1 min per kDa). e bloed membrane was blocked in 5 % milk in TBS-T for at least 30 min.
Antibodies were diluted in 5 % milk in TBS-T. e blot was incubated with the primary antibody
for at least one hour, if possible overnight. ereaer, the blot was washed with TBST-T three
times for 10 min and incubated with the secondary antibody for one hour. Aer three additional
washing steps with TBS-T, the blot was scanned at the Odyssey Infrared Imaging System (Biorad).
Towbin Bloing Buer 25 mM Tris, 192 mM glycine, 20 % methanol (pH 8.6)
TBS-T 10 mM Tris, 150 mM NaCl, 0.05 % Tween (pH 8)
For Coomassie staining, the SDS gel was placed in Coomassie Staining Solution for at least 1 h.
It was destained until protein bands were clearly visible. Samples for MS analysis were handled
with extreme care, i.e. use of clean gel running equipment and high purity SDS Running Buer,
Coomassie Staining, and Coomassie Destaining Solutions.
Coomassie Stain 10 % acetic acid, 30 % ethanol, 0.25 % Coomassie R250
Coomassie Destain 10 % acetic acid, 30 % ethanol
4.3.7 Mass-spectrometric analyses
All mass-spectrometric analyses were performed by the group of Prof. Dr. Rainer Deutzmann
(Biochemistry I, University of Regensburg).
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4.3.7.1 MS sample preparation
Gel bands were cut and transferred into 2 ml Eppendorf tubes containing freshly prepared 50 mM
NH4HCO3. e gel slices were washed for 15–30 min while shaking vigorously. NH4HCO3/AN
3:1 was used in the next washing step and the solution was exchanged until the gel slices had
lost their blue color. Aer washing with NH4HCO3/AN 1:1, the gel slices were washed with
100–200µl acetonitrile. e liquid was removed and the samples were lyophilized for 0.5–1 h.
Free cysteines were reduced by treating the samples with 200µl Reduction Reagent for 35 min
at 56 °C. e samples were carbaimdomethylated with 200µl freshly prepared Carbamidomethy-
lation Reagent for 35 min in the dark at room temperature. ereaer, the initial washing steps
with 50 mM NH4HCO3 and acetonitrile were repeated, the liquid was removed, and the samples
were again lyophilized.
For tryptic in-gel digest, 10–15µl trypsin working solution were added to the gel slices and
incubated at 37 °C until the gel was soaked with liquid (ca. 2 µg trypsin per 100 µl gel volume).
50 mM NH4HCO3 was added until the gel slices were covered well. e samples were incubated
overnight at 37 °C.
For elution steps, low-bind tips (Axygen Scientic Inc.) were used. e supernatant of the tryp-
tic digest was transferred to a new 0.5 ml reaction tube and 5 % formic acid was added to the
remaining gel slices until they were covered well. e second elution was incubated at 37 °C for
at least 30 min while shaking at 300 rpm. e supernatant was added to the rst eluate and a
third elution step was performed with NH4HCO3/AN 1:1. e unied elutions were lyophilized
and the lyophilisate was resuspended in 20µl of 5 % formic acid.
50 mM NH4HCO3 50 mM NH4HCO3
NH4HCO3/AN 3:1 75 % NH4HCO3 (50 mM), 25 % acetonitrile
NH4HCO3/AN 1:1 50 % NH4HCO3 (50 mM), 50 % acetonitrile
Reduction Reagent 1 mg/ml DTT, 50 mM NH4HCO3
Carbamidomethylation Reagent 5 mg/ml iodoacetamide, 50 mM NH4HCO3
trypsin stock solution 0.133µg/µl Trypsin Gold Mass Spectrometry Grade (Promega) solved in
1 M HCl
trypsin working solution 40µg/ml trypsin, 50 mM NH4HCO3
4.3.7.2 Mass spectrometers
e QTRAP 4500 (termed ’QTRAP’) is a hybrid triple quadrupole/linear ion trap mass spectrome-
ter, whereas the maXis plus UHR-QTOF (termed ’MAXIS’) is an ultra-high resolution quadrupole
time-of-ight mass spectrometer. Both mass spectrometers work with electrospray ionization
and are coupled to liquid chromatography systems (cf. subsection 4.1.6). Aer concentration on
a trapping column, peptides were separated by reversed-phase chromatography using a linear
gradient of 4 % to 40 % acetonitrile in 0.1 % formic acid at a ow rate of 300 nl/min, performed in
45 min (QTRAP) or 60 min (MAXIS).
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4.3.7.3 Mass-spectrometric measurements
For protein identication, samples were analyzed on the MAXIS mass spectrometer. Up to the
20 most abundant precursor ions were selected for fragmentation by collisional dissociation.
Phosphorylation sites of human Ago proteins were detected on both the QTRAP 4500 and the
MAXIS mass spectrometers by data-dependent analysis.
For quantication of Ago1-4, Ago-APP was applied in combination with an SRM-based method.
erefore, unique synthetic peptides applicable to human and murine samples were used as in-
ternal standard (peptides are listed in Tab. 4.7). An exactly quantied amount of the individual
stable isotope-labeled peptides was spiked into tryptic digests and incubated overnight at 37°C.
Ago1-4 quantication was performed on the QTRAP 4500 mass spectrometer.
4.3.7.4 MS data analysis
Data obtained on the MAXIS mass spectrometer were launched to MASCOT using the Protein-
Scape soware (Bruker Daltonics). Mascot (v2.3.02) was used to search the NCBI nr protein data
base or the SWISS-PROT nr database. Optionally, the search was restricted to certain taxa. Mas-
cot scores and expectation values were used to assess the reliability of identied proteins and
phosphorylation sites.
4.4 RNA-based methods
4.4.1 RNA isolation
For quantitative real time PCRs, RNA was extracted from inputs and anity-puried samples
with TRIzol® (ermo Fisher Scientic) according to the manufacturer’s guidelines. ereby,
TRIzol was directly added to the beads of anity-puried samples.
For cleavage assays and miRNA binding analyses, RNA was isolated aer protein digestion by
Proteinase K. erefore, 250µl Proteinase K buer (containing 40µg Proteinase K) were directly
added to the beads and incubated at 65 °C for 15 min. Next, 300µl of Roti®Aqua-Phenol/Chloro-
form/Isoamyl alcohol (25:24:1, Roth) were added. e samples were vortexed and centrifuged at
15,000 g for 10 min. e aqueous phase was transferred to a new reaction tube and 2.5 volumes
of ethanol and 1µl Glycogen RNA grade (ermo Fisher Scientic) were added. e RNA was
precipitated overnight at −20 °C (alternatively for 30 min at −80 °C) and thereaer pelleted by
centrifugation at 15,000 g for 30 min. e resulting pellet was washed with 70 % ethanol, air-
dried, and resuspended in water or RNA sample buer.
Proteinase K Buer 0.4µg/µl Proteinase K (ermo Fisher Scientic), 300 mM NaCl, 25 mM
EDTA, 2 % SDS, 200 mM Tris pH 7.5
2× RNA sample buer bromophenol blue and xylene cyanol in formamide
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4.4.2 antitative real time PCR (qRT-PCR)
For quantitative real time PCR, RNA from TRIzol extractions was resuspended in water. DNA
contaminants were digested with DNAse I for 30 min at 37 °C. DNase I was inactivated by addition
of EDTA and 10 min incubation at 65 °C. cDNA was synthesized by means of the iScriptTM cDNA
Synthesis Kit (Bio-Rad Laboratories), which was used according to the manufacturer’s protocol.
ereby, the total volume of RNA isolated from anity purications (IPs or APPs) was used.
1µg RNA was used for cDNA synthesis from input samples containing total RNA. Aer cDNA
synthesis, 20µl of cDNA were diluted with 30µl of water. Per sample, 2µl cDNA, each 0.6µl
forward and reverse primers, and 7.5µl SsoFastTM EvaGreen Supermix (Bio-Rad Laboratories)
were mixed in a total volume of 15µl. DNA amplication was monitored on a C1000TM thermal
cycler with CFX96TM real time detection system (Bio-Rad Laboratories).
For determination of ratios (fold changes), all possible ∆∆Ct ratios of sample triplicates and
the control triplicates were calculated. Errors are based on standard deviations, which were
determined from all received ratios (adapted from [230]).
4.4.3 RNA separation by urea PAGE and Northern Bloing
Dependent on the length of the investigated RNA, 8–18 % urea polyacrylamide gels (Urea Gel
Systems, National Diagnostics) were prepared according to the manufacturer’s protocols. e
gels were prerun in 1×TBE at 400 V, wells were washed thoroughly, and RNA samples (mixed
with 2× RNA sample buer) were loaded. For Northern Bloing, a loading volume of 20µl
per well was not exceeded. 8 % urea polyacrylamide gels were run at 400 V for ca. 1 h, 12 %
polyacrylamide gels for ca. 1.5 h, and 18 % polyacrylamide gels for ca. 5 h.
10×TBE 890 mM Tris, 890 mM boric acid, 20 mM EDTA
2× RNA sample buer bromophenol blue and xylene cyanol in formamide
Optionally, the urea gel was stained with ethidiumbromide for 10 min to assess RNA quality. For
bloing, three Whatman papers and an Amersham Hybond-N membrane (GE Healthcare) of the
same size were soaked in water and assembled on the positive electrode. e gel was rinsed with
water, transferred to the paper-membrane layer and covered with three more Whatman papers
soaked in water. Bloing was conducted at 20 V for 30 min. Aerwards, the miRNA 5’ ends were
crosslinked to the membrane [231]. erefore, an EDC crosslinking solution was prepared from
184 mg EDC (1-ethyl-3-(3-dimethyl-aminopropyl)-carbodiimid), 61.25µl 1-methylimidazol (12.5
M), 75µl HCl (1M) and H20 in a total volume of 6 ml. One Whatman paper was placed on plastic
lm and soaked with the freshly prepared EDC crosslinking solution. e membrane was placed
on the Whatman paper with the RNA side facing up and wrapped in plastic lm together with
the EDC-soaked paper. Crosslinking took place at 50 °C for 1 h. ereaer, the membrane was
gently washed with water and dried.
Probes were labeled by T4 Polynucleotide Kinase (ermo Fisher Scientic), which transfers the
terminal phosphate from 32P-γ-ATP to the 5’ end of the DNA oligonucleotide. e reaction was
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incubated at 37 °C for at least 30 min and stopped by addition of 30µl 30 mM EDTA. e probes
were puried by Sephadex G25 columns (GE Healthcare).
e membrane was prehybridized at 50 °C in hybridization solution. Aer about one hour, the
labeled probe was added and incubated with the membrane overnight at 50 °C. Aerwards, the
membrane was washed with Wash Buer I two times for each 10 min and with Wash Buer II
one time. It was wrapped in plastic lm, exposed to a screen and this was scanned at a phospho-
imaging system (BioRad).
ethidiumbromide staining so-
lution
1µg/ml ethidiumbromide in 1×TBE
20×SSC 3 M NaCl, 0.3 M trisodium citrate (pH 7)
50×Denhardt’s solution 1 % Bovine serum albumin fraction V, 1 % Polyvinylpyrrolidon K30, 1 % Ficoll
400
Hybridization solution 1×SSC, 20 mM Na2HPO4 pH 7.2, 7 % SDS, 1× Denhardt’s solution
Wash buer I 5×SSC, 1 % SDS
Wash Buer II 1×SSC, 1 % SDS
4.4.4 RISC cleavage assays
4.4.4.1 In vitro transcription
e composition of an in vitro transcription reaction is listed below.
In vitro transcription, 200µl
20 mM NTPs
10 mM DTT
1 % Triton X-100
2 mM Sperimidin
25 mM MgCl2
30 mM Tris/HCl pH 8
10µg template
0.2µl pyrophosphatase
20µg T7 RNA polymerase
A T7 RNA Polymerase puried by Dres. Nora Treiber and omas Treiber (both Biochemistry I,
University of Regensburg) was used for in vitro transcriptions. e reactions were incubated at
37 °C for 3–4 h. ereaer, 40 U DNase I (ermo Fisher Scientic) were added and incubated for
15 min at 37 °C to remove template DNA.
4.4.4.2 Cap-labeling of the target RNA
A perfectly complementary target RNA for miR-19b has been described before [72]. e DNA
template was cloned into a pUC18 vector and amplied by T7 and SP6 primers in a 250 µl PCR
reaction (Tab. 4.4. Aer gel separation, the appropriate band was excised and DNA was extracted.
For in vitro transcription, 400 ng of the DNA template were used. e in vitro transcribed RNA
was separated on an 8 % urea gel. e transcription product was visualized by UV shadowing,
excised, and eluted from the gel by addition of RNA Elution Buer. It was incubated at 65 °C for
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1 h while shaking. Aer gel elution, the liquid was transferred to a new reaction tube. e RNA
was precipitated with 2.5 volumes of ethanol and resuspended in water. e RNA concentration
was determined and working aliquots were stored at −80 °C.
For cap-labeling, the in vitro transcribed RNA was incubated in a 20µl cap labeling reaction for
4 h at 30 °C. e cap-labeled target RNA was again separated on an 8 % urea gel, visualized by
UV shadowing, excised, and eluted from the gel. Aer ethanol precipiation, the substrate was
disolved in ca. 20µl water and stored at −20 °C.
RNA Elution Buer
10 × GT buer 400 mM Tris pH 8, 60 mM MgCl2, 150 mM DTT, 20 mM spermidine
cap labeling reaction 1× GT buer, 50µg/µl target RNA, 25µM S-Adenosyl methionine, 0.5 U/µl
RiboLock RNase Inhibitor (ermo Fisher Scientic), 10 % guanylyltrans-
ferase, 1µCi/µl 32P-α-GTP
4.4.4.3 RISC cleavage assay
RISC cleavage assays were performed with 50 % (v/v) immunoprecipitated protein in 1× Trans-
lation Mix in a 20µl reaction. e cleavage reactions were started by addition of 1–2 Bq/cm2 cap-
labeled target RNA per sample. Aer incubation for 90 min at 30 °C, the reaction was stopped
by addition of 250µl Proteinase K Buer. e RNA was extracted using aqua-phenol/chloro-
form/isoamyl alcohol (25:24:1, Roth) and precipitated overnight with 20µg of glycogen RNA
grade (ermo Fisher Scientic). e RNA was pelleted by centrifugation, solved in 10µl of
formamide loading dye, and stored at −20 °C.
A partial RNase T1 digest of the radiolabeled target RNA was used as a ladder. erefore, 83.6µl
of the carrier RNA solution and 4µl of the RNase T1 dilution were mixed. is ’T1 Mix’ was
stored at−20 °C. e ladder was prepared by adding the same amount of radiolabeled target that
was used for a single cleavage reaction to 10µl of the T1 Mix. e digest was incubated at 50 °C
for exactly 10 min and immediately transferred to−20 °C. It was thawed only shortly before use.
Typically, 2µl of the T1 digest were loaded into one lane.
3 × Translation Mix 200 mM KCl, 20 mM MgCl2, 25 mM DTT, 5 mM ATP, 1 mM GTP, 0.5 U/µl
RiboLock RNase Inhibitor
Proteinase K Buer 0.4µg/µl Proteinase K (ermo Fisher Scientic), 300 mM NaCl, 25 mM
EDTA, 2 % SDS, 200 mM Tris pH 7.5
carrier RNA solution 25µM sodium citrate pH 5.0, 7.5 M urea, 1 mM EDTA, 0.1µg/µl yeast tRNA
(Ambion), 0.05 % bromophenol blue, 0.05 % xylene cyanol
RNase T1 dilution 25µM sodium citrate pH 5.0, 7.5 M urea, 1 mM EDTA, 5 U/µl RNase T1 (Fer-
mentas), 0.05 % bromophenol blue, 0.05 % xylene cyanol
4.4.4.4 Autoradiographic sequencing gels
Samples of in vitro RISC cleavage assays were resolved on 8 % sequencing gels (UreaGel System,
National Diagnostics). erefore, a SequiGen Sequencing Cell (21 × 40 cm, 0.4 mm spacers, 16-
well plastic comb, supplied by Bio-Rad Laboratories) was used. To facilitate gel pouring and
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disassembly, the glass plate connected to the buer tank was treated with Sigmacote® (Sigma-
Aldrich) before each use. To increase roughness of the opposing surface, the other glass plate
was regularly covered with 1 M NaOH and incubated with the solution overnight.
Each well was washed directly before loading. MiniFlex Flat tips (Sorenson BioScience) were
used to reach the boom of the well. Usually, 5µl of cleavage samples and 2µl of the T1 partial
digest were loaded. e gel was run at 50 W (approximately 1,700 V) until the bromophenol blue
front had reached the height of the lower plastic tank, ca. 8 cm from the boom of the gel. e
glass plates were disassembled and eventual wrinkles were carefully moved to the edges. Aer
transferring the gel onto a Whatman lter paper, it was covered with plastic lm, vacuum-dried
at 80 °C for 1 h, and exposed to a screen for up to 3 d.
4.5 Bioinformatic analyses
4.5.1 Sequence retrieval and alignments
e protein sequences that were used for alignments are listed below. e sequences were re-
trieved from www.uniprot.org and their accession codes within the database are indicated (as
of December 7th, 2014).
Homo sapiens AGO1, Q9UL18; AGO2, Q9UKV8; AGO3, Q9H9G7; AGO4, Q9HCK5
PIWIL1/HIWI, Q96J94; PIWIL2/HILI, Q8TC59; PIWIL3, Q7Z3Z3; PIWIL4/HIWI2,
Q7Z3Z4
Mus musculus AGO1, Q8CJG1; AGO2, Q8CJG0; AGO3, Q8CJF9; AGO4, Q8CJF8
Raus norvegicus AGO2, Q9QZ81
Caenorhabditis elegans ALG-1, G5EES3; ALG-2, O16720
Drosophila melanogaster AGO1, Q32KD4; AGO2, Q9VUQ5
Alignments were carried out by MAFFT version 7 (L-INS-i, scoring matrix BLOSUM62, gap open-
ing penalty 1.53, oset value 0.0) [232].
4.5.2 Homology models
A homology model of Ago1 as built by means of the I-TASSER server (version 2.1) [233], which
selected the human Ago2 structures (PDB 4EI1/4OLA and 4F3T) and Kluyveromyces polysporus
Argonaute (PDB 4F1N) as templates. e secondary structure content of the Ago1 homology
model and the Ago2 structures was determined by means of DSSP [185].
e homology models of human Ago3 and Ago4 were constructed by Prof. Dr. Rainer Merkl and
Lukas Kater (both Biochemistry II, University of Regensburg) by means of Yasara Structure (V
13.4.21) [234]. erefore, initial 3D-models were built on the basis of the human Ago2 and Ago1
structures (PDB IDs 4EI1/4OLA, 4F3T, 4KRE and 4KXT) [235, 236]. e models were rened by
means of loop modeling and side chain optimization. Subsequently, the best scoring fragments
were combined to deduce the nal homology models.
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PyMol (www.pymol.org) was used to analyze the 3D data sets of Ago structures and homology
models.
A. Appendix
Tables A.1–A.6 list phosphorylated peptides of all mass-spectrometric measurements summa-
rized in Fig. 2.18 and Tab. A.7 lists all phosphorylated peptides represented in Fig. 2.19. In case
of technical replicates, several elutions, or several analyzed Ago bands, duplicates were removed
and only the phosphopeptide with the highest score and lowest expectation value is listed. Phos-
phorylated residues are underlined. Non-unique peptides in Tables A.1–A.6 are indicated by
an asterisk. Measurements were conducted on two dierent mass spectrometers [QTRAP 4500
(ABSciex) and maXis plus UHR-QTOF (Bruker)] as indicated for each data set. is accounts for
dierent scores and expectation values. ese data should only be compared when measurements
were conducted on the same mass spectrometer.
Phosphosites that were retrieved from PhosphoSitePlus® (www.phosphosite.org) ar displayed
in Tab. A.8.
Table A.1: Phosphopeptides: Ago2-IP I, QTRAP
peptide score expectation value position in Ago2
YHLVDKEHDSAEGSHTSGQSNGR 71.45 0.00000072 S[824]
RPASHQTFPLQQESGQTVECTVAQY 47.63 0.00021 T[303], T[307], Y[311]
YHLVDKEHDSAEGSHTSGQSNGR 32.42 0.0053 S[828]
QILTYQLCHTYVR* 28.6 0.0086 T[783]
VGDTVLGMATQCVQM 28.25 0.0094 T[544]
EHDSAEGSHTSGQSNGR 25.04 0.018 S[824], S[828], S[834]
VGDTVLGMATQCVQMKNVQRTTPQTLS 23.36 0.058 S[561]
DVTGRVLQPPSILYGGR 23.24 0.042 T[409], S[417], Y[420]
SHQTFPLQQESGQTVECTVAQYFK 22.08 0.079 S[290], T[293], S[300], T[303]
LQPPSILYGGRNK 18.55 0.096 S[417]
KLTDNQTST* 18.22 0.069 T[363]
KLTDNQTSTM* 17.93 0.066 T[361], T[362], T[363]
SFFTASEGCSNP 17.2 0.071 S[180], T[183], S[185], S[189]
NTYAGLQ 16.46 0.042 Y[512]
HLKNTYAGLQ 15.96 0.077 T[511]
MMLNIDVSATA* 15.47 0.077 T[222]
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Table A.2: Phosphopeptides: Ago2-IP II, QTRAP
peptide score expectation value position in Ago2
SASFNTDPYVR 60.19 0.00000096 S[387]
DEMTDVTGRVLQPPSILYGGR 54.28 0.000011 T[409]
YHLVDKEHDSAEGSHTSGQSNGRDHQALAK 36.75 0.00021 T[830], S[831], S[834]
SIEEQQKPLTDSQR 32.99 0.0005 S[253]
VGDTVLGMATQCVQMK 29.12 0.0012 T[544]
YHLVDKEHDSAEGSHTSGQSNGRDHQALAK 28.29 0.0019 S[824], S[834]
YHLVDKEHDSAEGSHTSGQSNGRDHQALAK 27.11 0.0019 S[824], S[831], S[834]
YHLVDKEHDSAEGSHTSGQSNGRDHQALAK 26.82 0.0027 S[828]
PDFGTSGRTIKLQANFFEMDIPK 25.31 0.0066 T[33]
YHLVDKEHDSAEGSHTSGQSNGR 24.47 0.0036 S[831], S[834]
YHLVDKEHDSAEGSHTSGQSNGRDHQALAK 24.45 0.0036 S[828], T[830], S[831]
SFFTASEGCSNPLGGGR 22.3 0.0059 T[183]
PDFGTSGRTIKLQANFFEMDIPK 21.94 0.015 T[37]
YHLVDKEHDSAEGSHTSGQSNGRDHQALAK 21.4 0.01 S[834]
YHLVDKEHDSAEGSHTSGQSNGR 21.38 0.0073 T[830], S[831]
YHLVDKEHDSAEGSHTSGQSNGRDHQALAK 19.71 0.014 T[830]
YCATVRVQQHRQEIIQDLAAMVR 17.44 0.026 Y[625], T[628]
SFFTASEGCSNPLGGGR 17.43 0.018 S[185]
VGDTVLGMATQCVQMK 15.94 0.025 T[538]
VKFTKEIK* 15.45 0.029 T[259]
Table A.3: Phosphopeptides: TNRC6A–C Co-IP I (α-TNRC6A–C 11C12), MAXIS
peptide score expectation value position in Ago2
SFFTASEGCSNPLGGGR 84.54 0.00000025 S[180]
RPASHQTFPLQQESGQTVECTVAQYFK 65.44 0.000042 T[307]
HTYLPLEVCNIVAGQR* 65.37 0.000025 T[337]
WVSCVSLQALHDALSGR 63.46 0.000045 S[136]
VGDTVLGMATQCVQMK 61.54 0.000065 T[538]
FSSDELQILTYQLCHTYVR 58.51 0.00017 S[776]
TTPQTLSNLCLK 56.4 0.00017 T[556]
YPHLPCLQVGQEQK* 55.29 0.00027 Y[322]
SASFNTDPYVR 48.48 0.00094 S[387]
TTPQTLSNLCLK 45.88 0.002 T[555]
RPASHQTFPLQQESGQTVECTVAQYFK 42.27 0.009 T[303]
CIKKLTDNQTSTMIR 40.28 0.008 T[357]
RPASHQTFPLQQESGQTVECTVAQYFK 32.23 0.091 Y[311]
Table A.4: Phosphopeptides: TNRC6A–C Co-IP II (α-TNRC6A–C 7A9), MAXIS
peptide score expectation value position in Ago2
SFFTASEGCSNPLGGGR 63.32 0.00000047 S[180]
HTYLPLEVCNIVAGQR* 62.99 0.0000005 T[337]
Continued on next page
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peptide score expectation value position in Ago2
WVSCVSLQALHDALSGR 58.46 0.0000014 S[136]
SFFTASEGCSNPLGGGR 56.13 0.0000024 T[183]
SASFNTDPYVR 55.88 0.0000026 S[387]
TTPQTLSNLCLK 53.37 0.0000046 T[556]
TTPQTLSNLCLK 45.65 0.000027 T[555]
IDIYHYELDIKPEKCPR 44.94 0.000032 Y[55]
VGDTVLGMATQCVQMK 41.86 0.000065 T[538]
WVSCVSLQALHDALSGR 36.09 0.00025 S[139]
YPHLPCLQVGQEQK* 32.39 0.00078 Y[322]
FSSDELQILTYQLCHTYVR 30.87 0.00082 S[776]
VSIKWVSCVSLQALHDALSGR 25.08 0.0031 S[131]
RVGDTVLGMATQCVQMK 23.98 0.004 T[544]
RNKAIATPVQGVWDMR 22.35 0.0058 T[429]
YHLVDKEHDSAEGSHTSGQSNGRDHQALAK 19.95 0.014 S[828]
FFTASEGCSNPLGGGR 19.43 0.011 S[185]
RPASHQTFPLQQESGQTVECTVAQYFK 18.28 0.026 T[307]
HTYLPLEVCNIVAGQR* 16.99 0.02 Y[338]
YHLVDKEHDSAEGSHTSGQSNGRDHQALAK 15.62 0.037 S[824]
Table A.5: Phosphopeptides: Ago-APP I, QTRAP
peptide score expectation value position in Ago2
RVGDTVLGMATQCVQM 27.28 0.015 T[544]
NVQRTTPQTLSNLCLKI 27.21 0.027 T[555], T[556], T[559], S[561]
LTDNQTSTM* 24.38 0.014 T[361], S[362], T[363]
TTPQTLSNLCLKINVKLGGVNNILLP 23.51 0.058 T[559]
PNRYCATVRVQQHR 23.06 0.03 Y[625], T[628]
YHLVDKEHDSAEGSHTSGQSNGR 22.85 0.04 S[824]
HDALSGRLPSVPFETIQALDVVMR 20.87 0.09 S[153], T[158]
YTPVGRSFFTASEGCSNPLGGGR 20.68 0.075 S[185]
DGKKPSIAAVVGSMDAHPNR 20.66 0.073 S[610]
QEEISKLMRSASFNTD 20.63 0.083 S[380], S[387], T[390]
TSTMIRATAR 17.68 0.061 S[362], T[363], T[368]
SFFTASEGCSNP 17.2 0.082 S[180], T[183], S[185], S[189]
NVQRTTPQTLSNL 17.2 0.088 T[556], T[559]
QTSTMIRATARSAPDR 17.06 0.08 T[363]
VECTVAQYFK* 16.97 0.061 T[307]
TPVYAEVKRVGDT* 16.94 0.083 T[526], T[538]
EHDSAEGSHTSG 15.98 0.052 S[831]
LTDNQTST* 15.26 0.064 T[357]
AIATPVQGV 15.22 0.057 T[429]
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Table A.6: Phosphopeptides: Ago-APP II, QTRAP
peptide score expectation value position in Ago2
YHLVDKEHDSAEGSHTSGQSNGR 75.01 0.00000024 S[824]
ELLIQFYKSTRFKPT* 31.02 0.0069 T[657]
PSILYGGRNKAIATPVQGVWDMR 30.14 0.011 T[429]
VQRTTPQTLSNLCLK 20.46 0.055 T[555], S[561]
EHDSAEGSHTSGQSNGR 20.39 0.064 S[824], T[830], S[834]
KLTDNQTSTM* 20.25 0.041 T[361], S[362], T[363]
TTPQTLSNLCLKINV 18.26 0.092 T[555], T[556], T[559], S[561]
MYSGAGPA 18.22 0.024 Y[2], S[3]
QEEISKLMRSASFN 17.36 0.073 S[387]
RVGDTVLGMATQCV 17.27 0.086 T[538]
KLTDNQTSTMI* 16.60 0.085 S[362]
GSHTSGQSNGR 15.12 0.088 S[828], T[830], S[834]
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Table A.7: Phosphopeptides of Ago1–4
peptide score expectation value position in Ago1–4
Unique phosphopeptides of Ago1
MEAGPSGAAAGAYLPPLQQVFQAPR 57.61 0.0000018 S[6]
YHLVDKEHDSGEGSHISGQSNGRDPQ 35.83 0.0004 S[826]
YHLVDKEHDSGEGSHISGQSNGR 33.93 0.0004 S[822], S[826]
MEAGPSGAAAGAYLPPLQQVFQAPR 28.05 0.0017 Y[13]
YHLVDKEHDSGEGSHISGQSNGRDPQALAK 26.1 0.0025 S[822]
YHLVDKEHDSGEGSHISGQSNGRDPQALAK 23.74 0.0042 S[829]
YHLVDKEHDSGEGSHISGQSNGRDPQALAK 19.99 0.011 S[832]
YHLVDKEHDSGEGSHISGQSNGR 17.02 0.02 S[826], S[829]
YHLVDKEHDSGEGSHISGQSN 16.57 0.026 S[829], S[832]
Unique phosphopeptides of Ago2
SFFTASEGCSNPLGGGR 63.32 0.00000047 S[180]
WVSCVSLQALHDALSGR 58.46 0.0000014 S[136]
SFFTASEGCSNPLGGGR 56.13 0.0000024 T[183]
SASFNTDPYVR 55.88 0.0000026 S[387]
TTPQTLSNLCLK 53.37 0.0000046 T[556]
TTPQTLSNLCLK 45.65 0.000027 T[555]
IDIYHYELDIKPEKCPR 44.94 0.000032 Y[55]
VGDTVLGMATQCVQMK 41.86 0.000065 T[538]
WVSCVSLQALHDALSGR 36.09 0.00025 S[139]
FSSDELQILTYQLCHTYVR 30.87 0.00082 S[776]
VSIKWVSCVSLQALHDALSGR 25.08 0.0031 S[131]
RVGDTVLGMATQCVQMK 23.98 0.004 T[544]
RNKAIATPVQGVWDMR 22.35 0.0058 T[429]
YHLVDKEHDSAEGSHTSGQSNGRDHQALAK 19.95 0.014 S[828]
FFTASEGCSNPLGGGR 19.43 0.011 S[185]
RPASHQTFPLQQESGQTVECTVAQYFK 18.28 0.026 T[307]
YHLVDKEHDSAEGSHTSGQSNGRDHQALAK 15.62 0.037 S[824]
Unique phosphopeptides of Ago3
YHLVDKEHDSAEGSHVSGQSNGRDPQ 35.91 0,0004 S[829]
YHLVDKEHDSAEGSHVSGQSNGRDPQALAK 34.48 0,00036 S[825]
MEIGSAGPAGAQPLLMVPR 30.07 0,0011 S[5]
QVLYYELLAIREACISLEKDYQPGIT 27.77 0,0017 T[704]
VSWHLLHEVLTGR 24.52 0,0035 S[132]
YHLVDKEHDSAEGSHVSGQSNGRDPQALAK 23.74 0,0042 S[832]
YHLVDKEHDSAEGSHVSGQSNGR 23.69 0,0043 S[825], S[829]
YHLVDKEHDSAEGSHVSGQSNGRDPQALAK 19.99 0,011 S[835]
RPASHQTFPLQLENGQTVERTVAQYF 19.74 0,011 T[304]
LYTANPLPVATTGVDLDVTLPGEGGK 19.71 0,018 T[103]
Continued on next page
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Table A.7 – Continued from previous page
peptide score expectation value position in Ago1–4
YHLVDKEHDSAEGSHVSGQSN 16.57 0,026 S[832], S[835]
YHLVDKEHDSAEGSHVSGQSNGR 15.84 0,026 Y[816], S[825]
MWAIACFATQRQ 15.42 0,029 T[459]
Unique phosphopeptides of Ago4
YHLVDKDHDSAEGSHVSGQSNGRDPQ 23.83 0.0089 S[830]
YHLVDKDHDSAEGSHVSGQSNGRDPQALAK 21.76 0.011 S[826]
CNVTRRPASHQTFPLQLENGQAMECTVAQYFK 18.63 0.027 S[280], T[283]
Non-unique phosphopeptides of Ago1–4
HTYLPLEVCNIVAGQR 62.99 0.0000005 T[335] (Ago1)
T[337] (Ago2)
T[338] (Ago3)
T[327] (Ago4)
TQCVQVKNVVKTSPQTLSNLCLK 46.95 0.000029 T[553] S[554] (Ago1)
T[547], S[548] (Ago4)
TSPQTLSNLCLK 33.52 0.00044 S[554] (Ago1)
S[557] (Ago3)
S[548] (Ago4)
VGDTLLGMATQCVQVK 32.75 0.00053 T[536] (Ago1)
T[539] (Ago3)
T[530] (Ago4)
YPHLPCLQVGQEQK 32.39 0.00078 Y[320] (Ago1)
Y[322] (Ago2)
Y[323] (Ago3)
Y[312] (Ago4)
TSPQTLSNLCLK 27.11 0.0019 S[554] (Ago1)
S[557] (Ago3)
S[548] (Ago4)
VGDTLLGMATQCVQVK 23.8 0.0042 T[536] (Ago1)
T[539] (Ago3)
T[530] (Ago4)
HTYLPLEVCNIVAGQR 16.99 0.02 Y[336] (Ago1)
Y[338] (Ago2)
Y[339] (Ago3)
Y[328] (Ago4)
RVGDTLLGMATQCVQVK 16.75 0.021 T[542] (Ago1)
T[545] (Ago3)
T[536] (Ago4)
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Table A.8: Phosphopeptides of Ago1–4 as listed at PhosphoSitePlus®
sequence position detection method
context in Ago1–4 site-specic mass-spectrometric
Ago1
GQEQKHTYLPLEVCN Y[336] 0 3
IVILPGKTPVYAEVK T[524] 0 1
GSMDAHPSRYCATVR S[621] 0 1
HPSRYCATVRVQRPR T[626] 0 1
LVDKEHDSGEGSHIS S[822] 0 1
EHDSGEGSHISGQSN S[826] 0 2
Ago2
ALSGRLPSVPFETIQ S[153] 0 2
QQKPLTDSQRVKFTK S[253] 1 1
LQQESGQTVECTVAQ T[303] 1 1
SGQTVECTVAQYFKD T[307] 1 1
GQEQKHTYLPLEVCN Y[338] 0 3
QRCIKKLTDNQTSTM T[357] 0 1
EISKLMRSASFNTDP S[385] 0 3
SKLMRSASFNTDPYV S[387] 3 26
MRSASFNTDPYVREF T[390] 0 1
ASFNTDPYVREFGIM Y[393] 4 1
VVILPGKTPVYAEVK T[526] 0 1
LPGKTPVYAEVKRVG Y[529] 1 1
HPTEFDFYLCSHAGI Y[749] 0 1
EFDFYLCSHAGIQGT S[752] 0 1
sHAGIQGTSRPSHYH T[759] 0 1
HAGIQGTSRPSHYHV S[760] 0 1
VRCTRSVSIPAPAYY S[798] 1 1
LVDKEHDSAEGSHTS S[824] 0 1
EHDSAEGSHTSGQSN S[828] 0 1
SAEGSHTSGQSNGRD S[831] 0 1
Ago3
MEIGSAGPAGAQ S[5] 0 1
FFSAPEGYDHPLGGG Y[189] 0 66
AQYFREKYTLQLKYP Y[317] 0 1
KYTLQLKYPHLPCLQ Y[323] 0 1
GQEQKHTYLPLEVCN Y[339] 0 3
MRGKQFHTGVEIKMW T[445] 0 1
IVILPGKTPVYAEVK T[527] 0 1
GQFRQVLYYELLAIR Y[682] 0 2
QFRQVLYYELLAIRE Y[683] 0 6
DYQPGITYIVVQKRH Y[705] 0 1
LVDKEHDSAEGSHVS S[825] 0 3
EHDSAEGSHVSGQSN S[829] 0 2
Continued on next page
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Table A.8 – Continued from previous page
sequence position detection method
context in Ago1–4 Ago-specic proteomic screening
SAEGSHVSGQSNGRD S[832] 0 2
GSHVSGQSNGRDPQA S[835] 0 1
Ago4
LGPGPPASLFQPPRR S[11] 0 2
PKIDVYHYDVDIKPE Y[47] 0 1
DRVDMEVTLPGEGKD T[108] 0 1
GQEQKHTYLPLEVCN Y[328] 0 3
VVILPGKTPVYAEVk T[518] 0 1
TYVRCTRSVSIPAPA S[798] 0 1
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